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A B S T R A C T
Background
Restricting sodium intake in hypertensive patients over short periods of time reduces blood pressure. Long term effects (on mortality,
morbidity or blood pressure) of advice to reduce salt in patients with elevated or normal blood pressure are unclear.
Objectives
To assess in adults the long term effects (mortality, cardiovascular events, blood pressure, quality of life, weight, urinary sodium excretion,
other nutrients and use of anti-hypertensive medications) of advice to restrict dietary sodium using all relevant randomised controlled
trials.
Search methods
The Cochrane Library, MEDLINE, EMBASE, bibliographies of included studies and related systematic reviews were searched for
unconfounded randomised trials in healthy adults aiming to reduce sodium intake over at least 6 months. Attempts were made to trace
unpublished or missed studies and authors of all included trials were contacted. There were no language restrictions.
Selection criteria
Inclusion decisions were independently duplicated and based on the following criteria: 1) randomisation was adequate; 2) there was
a usual or control diet group; 3) the intervention aimed to reduce sodium intake; 4) the intervention was not multifactorial; 5) the
participants were not children, acutely ill, pregnant or institutionalised; 6) follow-up was at least 26 weeks; 7) data on any of the
outcomes of interest were available.
Data collection and analysis
Decisions on validity and data extraction were made independently by two reviewers, disagreements were resolved by discussion or if
necessary by a third reviewer. Random effects meta-analysis, sub-grouping, sensitivity analysis and meta-regression were performed.
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Main results
Three trials in normotensives (n=2326), five in untreated hypertensives (n=387) and three in treated hypertensives (n=801) were
included, with follow up from six months to seven years. The large, high quality (and therefore most informative) studies used intensive
behavioural interventions.
Deaths and cardiovascular events were inconsistently defined and reported; only 17 deaths equally distributed between intervention
and control groups occurred. Systolic and diastolic blood pressures were reduced at 13 to 60 months in those given low sodium advice
as compared with controls (systolic by 1.1 mmHg, 95% CI 1.8 to 0.4, diastolic by 0.6 mm hg, 95% CI 1.5 to -0.3), as was urinary 24
hour sodium excretion (by 35.5 mmol/ 24 hours, 95% CI 47.2 to 23.9). Degree of reduction in sodium intake and change in blood
pressure were not related. People on anti-hypertensive medications were able to stop their medication more often on a reduced sodium
diet as compared with controls, while maintaining similar blood pressure control.
Authors’ conclusions
Intensive interventions, unsuited to primary care or population prevention programmes, provide only minimal reductions in blood
pressure during long-term trials. Further evaluations to assess effects on morbidity and mortality outcomes are needed for populations
as a whole and for patients with elevated blood pressure.
A low sodium diet may help inmaintenance of lower blood pressure following withdrawal of antihypertensives. If this is confirmed, with
no increase in cardiovascular events, then targeting of comprehensive dietary and behavioural programmes in patients with elevated
blood pressure requiring drug treatment would be justified.
P L A I N L A N G U A G E S U M M A R Y
The long term effects of advice to cut down on salt in food on deaths, cardiovascular disease and blood pressure in adults
Intensive support and encouragement to reduce salt intake did lead to reduction in salt eaten. It also lowered blood pressure but only by
a small amount (about 1 mmHg for systolic blood pressure, less for diastolic) after more than a year. This reduction was not enough to
expect an important health benefit. It was also very hard to keep to a low salt diet. However, the reduction in blood pressure appeared
larger for people with higher blood pressure.
There was not enough information to assess the effect of these changes in salt intake on health or deaths.
Evidence from a large and small trial showed that advice to reduce salt helps to maintain lower blood pressure following withdrawal of
antihypertensive medication. If this is confirmed, with no increase in cardiovascular events, then comprehensive dietary and behavioural
programmes in patients with elevated blood pressure requiring drug treatment would be justified.
See also the Cochrane review of short-term salt reduction trials: Jurgens 2003.
B A C K G R O U N D
There is evidence from published systematic reviews that restrict-
ing sodium intake in people with elevated blood pressure leads
to reductions in blood pressure of about 4 mm hg systolic and 2
mm hg diastolic (Law 1991; Midgley 1996; Cutler 1997; Graudal
1998; Alam 1999; Jurgens 2003). However, within these reviews
many included trials are short term, neither allowing for complete
adjustment of blood pressure to altered sodium intake or to re-
ducedmotivation for following dietary restrictions over time. Also,
some trials increased sodium intake in one arm and compared this
with a reduced sodium intake in the other arm and so do not es-
timate likely effects of cutting down on sodium in a normal diet.
In addition, some reviews suggest that the level of blood pressure
reduction achieved over a longer period in free-living adults is less
impressive than in the short term (Ebrahim 1996; Ebrahim 1998;
Graudal 1998).
A decrease in blood pressure is only important if it results in a
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decrease in cardiovascular events and deaths. The published sys-
tematic reviews on the effect of salt restriction on blood pressure
and other risk factor outcomes have expressed different interpre-
tations with regard to the significance of these changes in relation
to cardiovascular events and deaths. This systematic review and
meta-analysis aimed to draw together information on the effect of
long-term dietary salt reduction on health outcomes.
O B J E C T I V E S
This systematic review aimed to study the effects of restricting
sodium intake over at least six months in free-living adults, com-
pared with a normal or usual sodium intake.
The specific objectives were to assess, in people with normal and
elevated blood pressure, the effect of advice and/or support to
reduce dietary sodium intake, on deaths and cardiovascular events;
number and dose of anti-hypertensive medications used; quality
of life; weight; systolic and diastolic blood pressure; and urinary
sodium excretion and other nutrient intakes in free-living adults
at least six months after the initial intervention was commenced.
The effects of potential modifiers of salt restriction (i.e. initial level
of blood pressure, categorization into normal or elevated blood
pressure, degree of sodium reduction, gender, race and age) were
also investigated.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All randomised controlled clinical trials (randomisation of indi-
viduals, or into at least six clusters) with at least 26 weeks of follow
up from initiation of intervention.
Types of participants
Studies of adults (16 years or older) with normal or raised blood
pressure were accepted. Participants were of either gender, but
those institutionalised, acutely ill or pregnant were excluded.
Types of interventions
The interventions included were designed to reduce sodium in-
take. The control group received a placebo intervention or no ac-
tive intervention. Studies were not included if they used a multi-
ple risk factor intervention intending to alter lifestyle or dietary
factors other than sodium (unless the effect of the low sodium diet
could be separated out from the other interventions). For example,
interventions that aimed to reduce sodium and increase potassium
were excluded, whilst in factorial interventions aiming to reduce
sodium intake and reduce weight, the low sodium arm (without
weight intervention) was compared to the control group (without
sodium or weight interventions).
Types of outcome measures
Primary outcomes:
Themain outcomes were total mortality and combined cardiovas-
cular events (including fatal and non-fatal myocardial infarction,
stroke, angina, heart failure, peripheral vascular events, sudden
death and non-scheduled cardiovascular interventions - coronary
artery bypass surgery or angioplasty). Both of these outcomes were
examined as relative risk in the intervention vs control group at
the latest time point available.
Secondary outcomes:
Changes in systolic and diastolic blood pressure (mmHg), quality
of life, weight (kg), nutrient intakes, urinary sodium excretion
(mmol/24 hours) and numbers and doses of anti-hypertensive
medication used. These were assessed at intermediate (6 months
to and including 12 months), late (13 to 60 months) and very late
follow up (over 60 months).
Search methods for identification of studies
Two searches were conducted, titles and abstracts scanned and
papers retrieved independently of each other. For the first search
(LH) the results of a previous large-scale search (Hooper 2000) for
dietary trials were used. This search scanned for trials on any di-
etary intervention and cardiovascular disease and included search-
ing of the Cochrane Library, MEDLINE, EMBASE, CAB Ab-
stracts, CVRCT registry, SIGLE to May 1998 plus bibliographies
of collected papers and reviews. It was updated for this review by
searching for systematic reviews or randomised controlled trials
on sodium manipulation and blood pressure in The Cochrane Li-
brary and MEDLINE (using randomised controlled trial filters):
DIET-SODIUM-RESTRICTED*:ME
SODIUM-DIETARY*:ME
(DIET* near (SALT* or SODIUM*))
((#1 or #2) or #3)
HYPERTENSION*:ME
HYPERTENS*
(#5 or #6)
(#4 and #7)
The second search (CB) looked specifically for trials on salt or
sodium restriction and blood pressure, and was run on MED-
LINE, EMBASE andTheCochrane Library. TheCochrane search
strategy (below) was used in conjunction with special search filters
to find randomised controlled trials onMEDLINE andEMBASE.
HYPERTENS*
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HYPERTENSION*:ME
(BLOOD near PRESSURE)
((#1 or #2) or #3)
DIET-SODIUM-RESTRICTED*:ME
SODIUM-CHLORIDE*:ME
(DIET* near ((SALT or SODIUM) or CHANGE))
(DIET* near (THERAPY or INTERVENTION))
(RESTRICT* near (SALT or SODIUM))
(LOWER* near (SALT or SODIUM))
(INTAKE* near (SALT or SODIUM))
(REDUC* near (SALT or SODIUM))
(((((((#5 or #6) or #7) or #8) or #9) or #10) or #11) or #12)
(#4 and #13)
Neither search was limited by language. Systematic reviews on di-
etary sodium and blood pressure were retrieved and bibliographies
of these and included studies scanned for further trials of at least
six months duration. Attempts were made to contact authors of
all included studies for details of further relevant trials that may
have been missed (either published or unpublished).
Data collection and analysis
Two reviewers (LH, CB) independently screened each article or
trial report with regard to the inclusion criteria. Articles were only
rejected on initial screen if the reviewer could determine from the
title and abstract that the article was not a report of a randomised
controlled trial; or the trial did not address a low sodium diet, or
the trial was exclusively in children less than 16 years old, pregnant
women or the critically ill; or the control group was not on usual
diet or placebo intervention; or the trial was of less than sixmonths
duration; or the intervention was multi-factorial. When a title or
abstract could not be rejected with certainty the full text of the
article was obtained for further evaluation.
Data extraction and quality assessment were performed indepen-
dently by two reviewers (CB, LH) onto forms designed for the
review (except for data on weight and other nutrients, which were
extracted by LH only). Disagreements were resolved by discussion
or if necessary by a third reviewer (SE).
Data extraction included details on population characteristics, in-
tervention and control procedures and outcomes of interest. Mor-
tality and cardiovascular event data were collected as events per
number of participants randomised to control and intervention
groups. Change in blood pressure, weight, other nutrient intakes
and sodium excretion from baseline to assessment period were col-
lected as continuous variables - number of subjects, mean change
in the outcome variable and standard deviation of the change for
both intervention and control groups. Data were collected on sys-
tolic and diastolic blood pressure changes, and urinary sodium
excretion, at intermediate (latest data point available from 6 to
12 months), late (latest data point available between 13 and 60
months) and very late (after 60 months) follow up.
Four trials (Costa 1981; Arroll 1995; Alli 1992; Morgan 1987)
provided baseline and follow-up values, with standard deviation
or standard errors, but no standard deviation for the change from
baseline. Using all of the three studies (Morgan 1978; TOHP
phase I; TOHP phase II) in which data were provided at baseline,
follow-up and mean differences given, values for the correlations
between baseline and change values (for the control and experi-
mental groups for systolic and diastolic blood pressure values but
not for urinary sodium excretion) were computed (Follman 1992).
A conservative estimate (lowest correlation) was used to compute
the standard deviation for the mean change for four studies (only
two of these were used in the meta-analyses). Correlations varied
(0.11 to 0.47 for systolic blood pressure in control groups, 0.07
to 0.56 for systolic blood pressure in experimental groups, -5.79
to 0.17 for diastolic blood pressure in control groups and -5.22
to 0.19 for diastolic blood pressure in experimental groups). The
negative correlations for diastolic blood pressure were due to ex-
tremely narrow ranges of diastolic blood pressure at baseline, re-
sulting in very small standard deviations, so that the assumption
that standard deviations at trial end would be similar were invalid.
For this reason calculated standard deviations were used only for
systolic blood pressure.
In factorial trials of calorie and sodium reduction only data from
the sodium reduction and control groups were used as, of three
such factorial trials (TOHP phase II; HPT; TONE), one reported
statistically significant interactions between the two interventions (
TOHPphase II), and another reported a ’suggestion of diminished
effect on blood pressure when sodium and calorie counseling were
combined’ (although this effect was not statistically significant)
(HPT). The exception was within the TONE trial, where data
on urinary sodium excretion were only available for the combined
groups, but where included event and medication data excluded
participants on calorie reduction interventions.
Quality assessment included information on randomisation pro-
cedure, allocation concealment, blinding of participants, providers
of care and outcome assessors and losses to follow up (Anonymous
2000). Where those recruiting participants into a trial appeared
unaware of the treatment allocation of those participants until
after recruitment was complete and where it was not possible to
alter allocation after treatment was assigned allocation conceal-
ment was judged ’adequate’. Other possibilities were ’inadequate’
or ’unclear’. Blinding of participants to their assigned treatment
was not possible, awareness of outcome assessors to the recipients
assigned treatment was judged ’no’ (equivalent to ’blinded’), ’yes’,
or ’unclear’. Numbers of participants lost to follow-up in each arm
were noted, as was the method used in the data analysis to adjust
for these losses.
Disagreements in data extraction or quality assessment were dis-
cussed and referred to another reviewer (SE) where necessary. At-
tempts were made to contact all authors of included studies for
further information on trial characteristics, quality and outcomes
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(where further information was not available numbers were ex-
tracted from available published figures and graphs).
Quantitative data synthesis
Primary measures of interest were the effects of dietary advice to
reduce sodium intake on
1. total mortality and
2. cardiovascular events and interventions.
For mortality and cardiovascular events, relative risks were used to
examine differences between low sodium and control groups using
the random effects model. For continuous outcomes, weighted
mean differences were examined, again using the random effects
model, on Cochrane Collaboration ReviewManager 4.1 software.
Meta-analyses were checked for heterogeneity by visual inspection
and by Cochran’s test.
Two trials were identified as being cluster randomised. In one small
trial, Alli 1992, 19 general practitionerswere randomised todeliver
simple low salt advice or no advice to a total of 77 patients. Patient
numbers in the intervention and control groups were reduced to
an effective sample size as described byHauck 1991, assuming the
intraclass correlation (appropriate for nonfamilial clusters such as
randomised practice units) to be 0.5 (Donner 1982). The other
cluster randomised trial was Thaler (which consisted of one pub-
lication, but the unpublished data provided were separated into
data for men, referred to as Thaler men 1982 and data for women,
Thaler women 1982). Individually randomised ’index’ men and
women included members of their families in the trial. Only the
’index’ participants were used in this meta-analysis.
Random effects meta-regression (Berkley 1995) was used to as-
sess the effect of initial level of systolic blood pressure, degree of
sodium reduction achieved, percentage female participants, per-
centage white participants and initial mean age on systolic blood
pressure (there were insufficient data on the primary endpoints,
death or cardiovascular events to make meta-regression on these
endpoints meaningful). Metaregression was performed using the
STATA command metareg (Sharp 1998).
Sensitivity analysis was carried out to assess the robustness of the
results to a) the exclusion of the data for which standard deviation
of the change was imputed, b) use of the largest correlations to es-
timate these standard deviations, c) the exclusion of trials with un-
known or inadequate allocation concealment (Anonymous 2000)
and d) inclusion of the weight and salt reduction arms of factorial
trials (where data for the appropriate [weight loss + low sodium] vs
[weight loss] comparison were added to a meta-analysis plot beside
the already included [low sodium] vs [control] comparison).
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies.
The 11 studies included within the review are described in the
table ’characteristics of included studies’. The number of publica-
tions assessed to come to these 11 studies and the outcomes that
were available in the 11 studies are shown in the Quorom Flow
Diagram which can be seen at this website: http://www.ti.ubc.ca/
PDF/A019QFD.pdf
Three trials in normotensives (n=2326, HPT; TOHP phase I;
TOHP phase II), five in untreated hypertensives (n=387, Morgan
1978; Costa 1981; Thaler (Thaler men 1982; Thaler women
1982); Silman 1983; Alli 1992) and three in treated hypertensives
(n=801, Morgan 1987; Arroll 1995; TONE) were included, with
follow up from six months to seven years.
The three normotensive trials were in healthy people (predomi-
nantly white, male, mean age 40) with high normal blood pres-
sure. Entry criteria varied between trials, but included those with
diastolic blood pressure from 78 to 89 mm hg, with a narrow
range of means from 83 to 86 mm hg diastolic and 124 to 127
mm hg systolic. All of the studies were conducted in the USA and
included from 392 to 1190 randomised participants.
All three studies (as well as TONE, below) ran comprehensive di-
etary and behaviour change programmes led by experienced per-
sonnel, including group counseling sessions, regularly over several
months, with newsletters between sessions, self assessment, goal
setting, food tasting and recipes. Control groups received no ac-
tive intervention. Sodium excretion goals were set at 70-80 mmol/
24 hours. For example, the HPT study ran ten weekly group
counseling sessions on food selection, food preparation and be-
haviour management skills, followed by semi-monthly and then
bi-monthly meetings throughout the trial (with newsletters in the
months where no meetings occurred). Sessions were run by nutri-
tionists and behavioural scientists and individual counseling was
provided where participants missed sessions or had special needs.
Techniques used in the sessions included group discussions, in-
structions for dietary record keeping, goal setting, individual diet
analysis for each participant, cooking demonstrations, provision
of recipe books and tasting of new foods.
The five trials in untreated hypertensives included people from 16
to 64 years, were carried out in Australia, New Zealand, Italy and
the UK and ranged in size from 28 to 164 participants. Entry cri-
teria ranged from unspecified ’untreated borderline hypertension’
(Costa 1981), diastolic blood pressure ranges within 90 to 109
mmhg (Morgan 1978; Silman 1983; Alli 1992) and systolic blood
pressure 137-180 mm hg (Thaler 1982). 42 to 100% of partici-
pants were male (not specified in two trials, Costa 1981; Silman
1983) and no trial described the ethnicity of its participants.
Interventions in the studies on untreated hypertensives included:
• individual counseling and a leaflet provided by a general
practitioner with reinforcement at each clinic visit , while the
control group maintained their usual diet (Alli 1992),
• a salt restriction programme for the whole family led by a
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nutritionist including a cookbook and individual counseling
(some at the family home) with provision of low sodium baking
powder and baking soda and low sodium bread provided weekly
by a local baker, while the control group were asked to eat their
usual diet (Thaler 1982),
• a general health education package (on healthy eating,
smoking, exercise and stress control) with teaching about a low
fat diet (diet sheet provided) compared with the general health
education package only in the control group (Silman 1983),
• given a low salt diet (no details provided) compared with
advice on a diet with free salt in the control group (Costa 1981),
• instructions to reduce dietary sodium chloride intake, with
advice repeated at 3 months (no further details provided)
compared with no intervention in the control group (Morgan
1978).
Sodium goals varied from <80 mmol/24 hours to <100 mmol/24
hours of urinary sodium excretion, 3 g NaCl per day and 70-100
mmol/24 hours of sodium intake.
The three trials in treated hypertensives had mean ages of 55 to
67 years, were carried out in Australia, New Zealand and the USA
and ranged in size from 20 to 641 participants. Entry criteria var-
ied, diastolic blood pressure was 70-105 mm hg or systolic blood
pressure 155-180 mm hg while taking antihypertensive treatment
(Arroll 1995), diastolic blood pressure <85 mm hg while taking
antihypertensive treatment and >100 mm hg without treatment
(Morgan 1987) or <85 mm hg diastolic and <145 mm hg systolic
bloodpressurewhile taking antihypertensivemedication (TONE).
49-100% of participants were male and 76% were white in the
TONE study (ethnicity was not mentioned in the other studies).
Interventions in trials of treated hypertensives included:
• being asked to reduce use of high salt foods, salt at table and
in cooking, given an article on blood pressure and salt restriction,
a leaflet and a book with sodium contents of common foods,
compared with no intervention in the control group (Arroll
1995),
• a low sodium diet (no further details provided) compared
with a normal diet in the control group (Morgan 1987), and
• an individual nutrition and behavioural counseling
programme (as above) or no such programme but with
invitations to meetings on unrelated topics in the control group
(TONE).
Sodium goals were dietary intake of 50-75 mmol/24 hours
(Morgan 1987), urinary sodium < 80 mmol/24 hours (TONE)
and unspecified (Arroll 1995).
Excluded studies (where the full text paper was collected) were
excluded on the basis of no follow up after six or more months
(28 studies), having a multifactorial intervention where the effects
of salt reduction advice could not be separated from other inter-
ventions (17 studies), lack of randomisation (10 studies), lack of
an appropriate ’usual diet’ control group (10 studies) or inclusion
of children (one study). Studies were often excluded for several
reasons, but one main reason has been provided for each study in
the list above.
Risk of bias in included studies
Trial quality as judged by allocation concealment appeared higher
in the trials on normotensives (allocation concealment adequate
in three of three trials, compared to one of three trials in treated
hypertensives and zero of five trials in untreated hypertensives).
Other aspects of trial quality assessed included blinding of out-
come assessment and losses to follow up. Different methods of
dealing with missing data associated with losses to follow up were
apparent. Themajority of trials attempted to blind outcome asses-
sors. For further details of individual study quality see the ’Notes’
section of the Table of Characteristics of Included Studies.
Effects of interventions
Mortality and cardiovascular events
These outcomes were inconsistently reported in trials (see Table
1). No differences in periods of hospitalisation were seen between
intervention groups in the HPT study (no further data were pro-
vided). Morgan 1978 reported that three control participants were
treated for cardiac failure, as were two on low sodium diets, with
four cardiovascular deaths in the low sodium group and two in the
control group. TONE recorded cardiovascular events (including
stroke, transient ischaemic attack, myocardial infarction, angina,
congestive heart failure, arrhythmia and ’other’ events) of partic-
ipants. Cardiovascular events occurred in 46 control participants
and 36 of those on low sodium diets. Pooling the two studies sug-
gests no significant difference in cardiovascular morbidity between
low sodium and control groups (relative risk 0.82, 95% CI 0.56
to 1.21).
The trials report few deaths, altogether only 9 deaths in control
groups and 8 in low sodium groups (relative risk 0.90, 95% CI
0.36 to 2.24). The available data are shown in metaview.
Blood pressure
Changes in blood pressure and urinary sodium excretion at in-
termediate and late assessments are given in Table 2 and meta-
analysis results in Table 3. Systolic blood pressure was reduced on
a low salt diet at both intermediate (by 2.5 mm hg, 95% CI 3.8
to 1.2) and late follow up (by 1.1 mm hg, 95% CI 1.8 to 0.4).
Diastolic blood pressure was also reduced at intermediate follow
up (by 1.2 mm hg, 95% CI 1.8 to 0.6), less so later (by 0.6 mm
hg, 1.5 to -0.3).
The few participants with very late follow up (seven years) had
non-significant reductions in systolic (by 3.8 mm hg, 95% CI
7.9 to -0.3) and diastolic (by 2.2 mm hg, 95% CI 4.8 to -0.4)
blood pressure. It should be noted that this late follow up of the
TOHP phase I study was technically after the end of the trial.
6Advice to reduce dietary salt for prevention of cardiovascular disease (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
TOHP phase I ran for 18 months with a consistent intervention
to help the low sodium group stick to a low sodium diet. The 7-
year results are described as ’posttrial’ results, and as 7 years follow
up, and the trialists implied that they were assessing the long term
effect of their 18 month intervention. We (as reviewers) felt that
if the trial just stopped intervening, without altering the diets of
either the intervention or control groups then we could include
data from the later follow up (in many studies the intervention
only happens once or twice at the beginning, but the effect is
measured months later). The paper states that ’after 18-months,
there was no further contact with the trial participants to enhance
the intervention effect’. We could not contact the reviewers to
confirm that there were no suggested alterations to the diets of the
participants after the eighteen month intervention, so the data are
included here but with this note of caution.
Statistical heterogeneity was present for systolic blood pressure at
intermediate follow up and diastolic blood pressure at late follow
up, but was resolved when sensitivity analyses removed trials with
inadequate or unclear allocation concealment, or with imputed
standard deviations, or when trials were sub-grouped into nor-
motensive or hypertensive at baseline.
Sensitivity analysis, excluding trials with inadequate allocation
concealment, resulted in all trials on untreated hypertensives being
removed. As these trials were small, the effect on pooled estimates
of blood pressure change was minor. Adding in data for the weight
reduction arms of factorial trials strongly reduced the effect of low
sodium advice on blood pressure, and slightly reduced the effect
on sodium excretion (Table 3).
Meta-regression of blood pressure change up to 12 months using
all trials with relevant data (or trials with adequate allocation con-
cealment, effectively trials on normotensives) showed no relation-
ship with change in urinary sodium excretion, baseline systolic
blood pressure or age (Table 4). However, the meta-analyses sub-
grouping by ’normotensive’ or ’hypertensive’ participants at base-
line did suggest a consistently greater effects of salt restriction on
blood pressure in hypertensives. Insufficient data were available of
effects on specific races or genders to enable statistical exploration
of these factors.
Quality of Life
Information on quality of life was patchy, with no common out-
comemeasures. HPT asked participants whether they were having
problems with their diets. 69% of those in the low sodium group
reported problems at some time during the 3 years of the trial, and
problems were reported at 42% of clinic visits. Problems related
to the diet being inconvenient, conflicting with schedules, lack of
time for planning, and difficulty in adherence while eating out.
TOHP phase I reported psychological well-being scores. These
improved significantly in participants in the low sodium groups
at 18 months compared with the non-intervention control group
(p<0.01). It was stated that the improvement was generally con-
sistent across race and sex subgroups but no further information
was provided.
Thaler (Thaler men 1982; Thaler women 1982) reported that
stopping adding salt at table was not difficult for participants, but
many found cutting down on salt in cooking harder. The majority
found their low salt bread (salt cut from 2.1% to 1.0% dry weight)
and salt-free butter acceptable. Only 13% of participants reported
their salt restricted diet as unpleasant or worse.
TONE found that the most common non-cardiovascular event
recorded was headache: the low sodium group had a significant
reduction in headaches as compared to the control group.
Thaler (Thaler men 1982; Thaler women 1982) asked about pres-
ence or absence of muscle cramps in control and low sodium par-
ticipants. At eight months 13% of control subjects reported get-
ting cramps a lot or sometimes (as opposed to occasionally or
never) whilst this outcome was reported in 30% of the low sodium
group.
Overall drop out rates were very similar (relative risk 1.04, 95%
CI 0.86 to 1.25) in low sodium compared with control groups.
Weight
The suggestion from food diaries in HPT was that men on a low
sodium diet take in roughly 240 kcal less per day than their control
counterparts. Women on low sodium diets take in 120 fewer kcal
per day. This did not result in a large difference in weight; at 3
years those in the control group had gained about 1 kg on average
more than those in the low sodium group.
TOHP phase I observed significantly greater weight loss in the low
sodium group compared with control at six (1.2 kg) and twelve
(0.8 kg) months, but the difference at 18 months (0.4 kg) was
no longer significant. Similarly, in TOHP phase II those on a
low sodium diet lost more weight initially (1.2 kg difference at
6 months, p<0.001), but the difference had disappeared by 36
months.
Arroll 1995 found a weight loss of 1.4 kg in the low sodium group
relative to the controls at six months. However, Morgan 1987,
Thaler (Thaler men 1982; Thaler women 1982), and Silman
1983, found no change in weight in either control or low sodium
groups.
In TONE eight participants not assigned to a weight loss inter-
vention experienced excessive weight loss, but it is not clear how
many of these were in the control or low sodium groups.
Overall, in the larger studies, where one ismore likely to see any real
effect, there appeared to be initial weight reductions accompanying
the low sodium diet, but the effect was lost over several years.
Urinary sodium excretion
Meta-analysis demonstrated a reduction in urinary 24 hour
sodium excretion at intermediate (48.9 mmol/ 24 hours, 95% CI
65.4 to 32.5), and late follow up (35.5 mmol/ 24 hours, 95% CI
47.2 to 23.9) in those advised to follow a low sodium diet com-
pared with control. Significant heterogeneity was seen in results at
intermediate and late assessment, and was not resolved by sensitiv-
ity analysis leaving out trials with unclear or inadequate allocation
concealment. The one trial to assess very late outcomes (TOHP
phase I, in normotensives) found that at seven years sodium ex-
7Advice to reduce dietary salt for prevention of cardiovascular disease (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
cretion in a small subset of their original sample was similar in
intervention and control groups.
Other nutrients
The relationship between low sodium dietary advice and other
dietary components has not been fully explored in these studies.
Potassium is the most reported component, usually measured as
urinary excretion alongside sodium. Other nutrients were mea-
sured as dietary intakes using food record and recall systems.
Minerals
Potassium. In HPT potassium excretion was consistently greater
in low sodium than control groups (about 6 mmol/24 hours at
3 years) but whether this difference was statistically significant
is not clear. In TONE potassium intake was also greater in the
low sodium group than in control (by 160 mg/24 hours, 95% CI
25 to 295). The rest of the trials found no significant differences
in reported intakes or excretion of potassium including: TOHP
phase I, TOHP phase II, Thaler men 1982, Thaler women 1982,
Morgan 1978, Morgan 1987 and Silman 1983.
Magnesium. TONE found a higher intake of magnesium in low
salt as compared with control groups (by 24 mg/24 hour, 95% CI
8 to 39), whereas TOHP phase I reported no significant difference
between groups.
Calcium. TONE found a significant fall in calcium intake in the
low salt as compared with the control group (of 71 mg/24 hours,
95% CI 119 to 23). HPT found a reduction in salt from dairy
foods (suggested in all groups, but only significant in normal
weight men), while TOHP phase I reported no significant net
differences in reported intake of calcium.
Iron. TOHP phase I reported lower intakes of iron (3.6 mg/day
at 18 months) in the low sodium group. The differences in iron
were due to differences in men (women were similar between low
sodium and control groups) and the reported iron intakes (15 mg/
day at 18 months in men) in the low sodium group were still well
over the RDA (10 mg/day for men). TONE also found lower iron
intakes in the low sodium group (lower by 2.8 mg/24 hours, 95%
CI 3.8 to 1.8).
Phosphorus and zincwere not significantly different in low sodium
and control groups in TONE.
Vitamins
TOHP phase I reported no significant net differences in reported
intakes of vitamin A, vitamin C, thiamine, riboflavin or niacin.
TONE found lower intakes of thiamine (0.12 mg/24 hours, 95%
CI 0.22 to 0.02) and riboflavin (0.2 mg/24 hours, 95% CI 0.3
to 0.1) in low sodium groups, but no significant differences in
vitamins A, Bs, C, D, E, folate or niacin (excluding supplements).
Macronutrients
Energy. TOHP phase I reported significantly lower daily intakes
of total energy (207 kcal) in the low sodium group, as did TONE
(by 119 kcal/24 hours, 95% CI 197 to 41).
Fats. Lower intakes of total fat (by 5.8 g/24 hours, 95% CI 10.1
to 1.5), saturated fat (by 2.4 g/24 hours, 95% CI 4.0 to 0.8) and
monounsaturated fat (by 2.2 g/24 hours, 95% CI 4.0 to 0.4) were
seen in the low sodium group of TONE.No significant differences
were seen in polyunsaturated fat intake. TOHP phase I reported
significantly lower daily intakes of total fat (11.4 g) in the low
sodium group, but no significant net differences in saturated fat.
Alcohol. TOHP phase II reported that there were no differences
between the low sodium and usual care groups in alcohol intake,
while Arroll 1995 reported an increased intake of alcohol in the
control group (2.4 g/day), though it was not clear whether this
was statistically significant. TOHP phase I reported no significant
net differences in reported intake of alcohol.
Protein and carbohydrates were not significantly different in the
low sodium and control groups in TONE.
Overall, there is a trend towards increases in potassium and mag-
nesium, and a fall in calcium, iron, some B vitamins, total energy,
total and saturated fats in low sodium groups.
Anti-hypertensive medications used
Two trials in patients with elevated blood pressure considered
the ability of low salt diets to maintain blood pressure con-
trol after stopping anti-hypertensive medication. In the smaller
trial (Morgan 1987) anti-hypertensive therapy was stopped two
months after randomisation to usual or low sodium diet, but
restarted if diastolic blood pressure rose. After six months, four of
ten men on low sodium diet were taking anti-hypertensive med-
ication, compared to nine of ten on usual diet (relative risk 0.44,
95% CI 0.20 to 0.98).
In the larger study (TONE, 975 participants, including those on
weight reduction interventions) withdrawal of medication was at-
tempted 3 months after randomisation to low sodium diet (with
behavioural therapy) or usual care. The primary combined end-
point (a combination of high blood pressure at any visit, restart-
ing of anti-hypertensive medication or any clinical cardiovascular
event) was less common in the low sodium group, relative risk
0.83 (95% CI 0.75 to 0.92), ARR 14%, NNT 7.
D I S C U S S I O N
Eleven long term randomised controlled trials of dietary salt reduc-
tion (including 3514 participants) provided few data on mortality
(17 deaths in total), cardiovascular events or quality of life, but
did demonstrate a significant decrease in systolic blood pressure
(1.1 mm hg, 95% CI 1.8 to 0.4) and urinary sodium excretion
(35.5 mmol/24 hours, 95%CI 47.2 to 23.9) at 13 to 60 months
after initial advice. The decrease in diastolic blood pressure was
smaller (0.6 mm hg, 95% CI 1.5 to -0.3). The data suggest that a
low salt diet may help people on anti-hypertensives to stop their
medication without losing blood pressure control. The data from
TONE suggest that for every 7 patients assigned a goal of achiev-
ing a sodium intake of less than 80 mmol/day, one would remain
off antihypertensive medication with a BP less than 150/90 mm
hg and with no adverse cardiovascular events.
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Effects of low salt dietary advice on mortality and cardiovas-
cular morbidity
Health promotion interventions involve several stages before any
health outcome is seen. First, the advice must result in changed
behaviour (cutting down on salt in foods) and secondly that be-
haviour must result in an improved health outcome (reduced car-
diovascular illness, increased life expectancy). A major weakness
of this review is that we were not able to assess the overall effect
of advice to reduce dietary sodium on mortality or morbidity (as
not enough events have been accumulated to see any definitive
answer). Instead we have tried to follow the process by assessing
several intermediate outcomes including urinary sodium excretion
and blood pressure; however there may be effects on other risk
factors.
It is not clear what effects a low sodium diet has on cardio-
vascular events and mortality. It has been suggested that lower-
ing sodium intake may have adverse effects on the vascular en-
dothelium through stimulation of the renin-angiotensin system
(Alderman 1997), and adverse effects on serum total and LDL
cholesterol levels (Graudal 1998) have been suggested. In cohort
studies, lower salt intake in hypertensives has been associated with
higher levels of cardiovascular disease (Alderman 1995) and in
general populations (Alderman 1998; Tunstall-Pedoe 1997) with
greater all-cause mortality. However, among obese people lower
salt intake may be associated with reduced risk of cardiovascular
events (He 1999; Tuomilehto 2001). These apparently contradic-
tory findings emphasizes the fact that we do not know whether
long-term salt restriction is beneficial or harmful.
Effects of low salt dietary advice on sodium excretion
The review suggests that sodium reduction of about a quarter of
usual sodium intake in US and UK populations (MAFF 1999)
can be achieved long term. This may be exaggerated. For example,
HPT found that 48% of participants ate differently on the day of
their food record, eating less food, and substituting simpler foods.
Several people in the low sodium group also reported eating less
salt on days salt intake was recorded. Whether food adjustment
also occurred when urine samples were collected (and whether
these were complete) is not known. Male participants in Thaler’s
trial (Thaler men 1982) were believed to have relaxed their salt
restriction between urine samples (O. Simpson, personal commu-
nication, 2001).
Is it realistic to ask people to alter their salt intake long term?
Advice to reduce dietary salt is common in primary care if the
British Hypertension Society’s Guidelines (Ramsay 1999; Ramsay
1999a) are being followed. These guidelines advise that ’reduced
use of salt when preparing food and elimination of excessively salty
foods from the diet’ ’be offered to all hypertensive people and those
with a strong family history of hypertension’. It does appear that
the degree of salt restriction attained attenuates over time (Table
3) and this occurs despite a great deal of ongoing encouragement
and support (comprehensive interactive programmes of dietary
andbehavioural education involving specialized andhighly trained
staff, vast input of skills, time and materials) in all of the four large
high quality trials. The resulting falls of 1.1mmhg systolic and 0.6
mm hg in diastolic blood pressure may be useful at a population
level; however the intensity of intervention applied to individuals
required to achieve this is not realistic for community control of
high blood pressure, which would need to be through changes in
food production and catering practices.
Effects of low salt dietary advice on blood pressure
While both urinary sodium excretion and blood pressure fell, the
salt reductionmay not have caused the fall in blood pressure. Alter-
ations in diet aimed at reducing salt intake may perhaps systemati-
cally affect other dietary components (such as alcohol, potassium,
calcium, fat or energy intake) thatmay themselves alter blood pres-
sure (Cappuccio 1991; Allender 1996; Whelton 1997; Ebrahim
1998; Brand 1999; Griffith 1999). The only available data sug-
gest that potassium is not consistently affected by a low sodium
diet, and that weight may be reduced in the medium term, but
is unlikely to be exerting much effect on blood pressure by three
years. Very little information is available on alcohol (suggesting
no major effect), calcium (TOHP phase I reported no significant
changes in intake of calcium, but HPT reported a reduction in
salt from dairy foods) or fat (suggesting that significant reductions
may be occurring in low sodium groups, reported in only one
large trial). The significant reduction in weight of people given low
sodium dietary advice in the medium, but not the longer term,
may explain why the effect of a low sodium diet on blood pressure
’drops off ’ so much between intermediate and late follow up in
this review. It may also explain why, in this review, no relationship
is seen between the degree of reduction in sodium excretion and
change in blood pressure. However the number of trials is small
and relating a mean change in blood pressure to a mean change
in urinary sodium is statistically weak. In previous meta-analyses
(Table 5) a relationship has been seen in some cases but not in
others. Individual participant data are required to take this issue
further.
We expected that short duration trials would achieve larger falls in
blood pressure that would attenuate over time, in line with atten-
uation of salt restriction. Trials in normotensives in in the Graudal
review (Graudal 1998) (Table 5) had a median length of 8 days, a
reduction of 160 mmol/24 hours in urinary sodium excretion and
a fall of 1.2 mm hg in systolic blood pressure, while in this review
(median trial length 36 months, 34 mmol/24 hours difference in
sodium excretion) systolic blood pressure fell by 1.1 mm hg. In
hypertensives our results are less easy to interpret due to the low
quality of included studies, but there is no clear suggestion that
blood pressure effects diminish with longer duration trials or with
smaller reductions in sodium excretion. This suggests that home-
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ostatic mechanisms (Navar 1997) do not operate over the longer
term to re-set usual blood pressure levels as might be expected. It
has been suggested that ’usual’ blood pressure may be set in utero
or early childhood (Barker 1998) so it is possible that dietary salt
intake in early childhood has a greater role in determining adult
blood pressure than salt intake in adulthood; however the evidence
is mixed (Lucas 1988; Hofman 1983; Singhal 2001), and open
to varying interpretations (He 2001). A systematic review in this
area would be helpful.
Part of the blood pressure lowering effect at longer follow up may
be due to lower sodium diets preventing blood pressure rise with
age. The Intersalt observational study (Elliott 1996) suggested that
a population excreting 100 mmol/day less sodium would experi-
ence a 10 and 6 mm hg lower rise in systolic and diastolic blood
pressure over 30 years. This review suggests that voluntary reduc-
tion of only 35 mmol Na/ 24 hours is realistic for periods of over
one year. This would prevent 3-4 mm hg systolic (2 mm hg dias-
tolic) blood pressure rise over thirty years. However, the sodium
reduction achieved may decline over time so this additional pro-
tective effect of low salt advice may be limited.
The sodium reduction arms of the DASH (Sacks 2001) study are
not included in this review as their intervention periods were only
30 days; however the strength of the study was in providing all
food for participants and so tightly regulating sodium (as well as
potassium and calorie) intake. Participants in the ’control inter-
mediate sodium’ arm reduced their sodium excretion by 35mmol/
day compared with the ’control normal sodium’ arm, reducing
systolic (2.1 mm hg, 95% CI 3.4 to 0.8 mm hg) and diastolic (1.1
mm hg, 95% CI 1.9 to 0.2 mm hg) blood pressure by amounts
similar to those seen in 13-60month followup in this review.With
greater reductions in sodium, systolic blood pressure decreased by
a greater amount ( 6.7 mm hg. 95% CI 5.4 to 8.0).
Effects of low salt dietary advice on other outcomes
There is evidence that a low sodium diet improves the chance
of maintaining controlled blood pressure following withdrawal of
antihypertensives.
There are several reasons for assessing levels of other nutrients in
a low sodium diet. Altering any one component of a complex diet
will in turn alter the intake of many other micro and macro-nu-
trients. It is important to ensure that a low sodium diet is nutri-
tionally adequate. It is also necessary to be aware that changes in
many nutrients have their own long term effects on blood pressure
and other aspects of cardiovascular health. The available data are
scant but suggest increases in potassium and magnesium intake,
and reductions in energy and total fat intakes, all of which might
be expected to help reduce blood pressure in their own right as well
as protecting against cardiovascular disease in other ways. This is
good news for health, but raises further questions about the extent
of the effect of salt reduction itself on blood pressure. It may be
that the small changes in blood pressure seen in these long term
trials are due to increases in potassium and decreases in fat intake.
On the other hand, the reductions in calcium and iron seen in
some trials might endanger dietary adequacy for a few people, in-
creasing the risk of osteoporosis and anaemia. It may be that the
effect on blood pressure, and more generally on health, of a low
sodium diet depends on the types of messages used, the specific
dietary measures taken. These may differ considerably from trial
to trial, or even from participant to participant.
We have included only a small number of the many randomised
controlled trials on the effect of salt manipulation, and none of the
intra- or inter-population surveys, cohorts or animal trials that are
commonly referred to when the effect of salt reduction on health is
discussed. Most of the randomised controlled trials that have been
performed have been of short duration and do not assess whether
dietary advice has any long term effect on health outcomes or
blood pressure. Despite an extensive search, only eleven trials ful-
filled our inclusion criteria (determined by our question). Where
randomised controlled trials in humans are available to answer a
question on health, it would be inappropriate to include animal
studies, surveys or cohort studies, which have contradictory results
and interpretations (Taubes 1998).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Two trials suggest that a low sodium diet helps in preventing ele-
vated blood pressure following withdrawal of antihypertensives. If
this is confirmed, with no increase in cardiovascular events, then
targeting of comprehensive dietary and behavioural programmes
at this group would be justified.
Long term maintenance of low sodium intake for individuals is
difficult even with a great deal of support, advice and encourage-
ment. A policy of reduction in salt intake for the entire popula-
tion, through cutting salt levels in processed foods (MacGregor
1996), as recently announced by the UK’s Chief Medical Officer
(DoH 2001), is potentially a way of achieving small reductions in
blood pressure across the whole population for sustained periods
of time. Individual reduction of risk would be small, but across
a whole population the effects may be substantial (Stamler 1991;
Selmer 2000).
However, raised blood pressure is only one risk factor for cardio-
vascular disease and overall clinical benefits (or harms) of a reduced
sodium diet are unclear - further research is urgently needed to
explore this. Deaths and cardiovascular events in the long-term
RCTs published to date were too infrequent to answer whether
the benefits of sodium restriction outweigh the harms.
Implications for research
Follow up of all participants of the large trials some years later to
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assess long term effects of low sodium dietary advice on mortality
and cardiovascular morbidity would be a cost effective and timely
way to assess the clinical effect of low sodiumadvice. There remains
a strong justification for a large, long term RCT to explore the
effect of reduced sodium advice on these outcomes in people with
borderline and mild elevations of blood pressure.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Alli 1992
Methods RCT: GPs were ’selected at random’ (GPs were randomised, not participants, 9 gave dietary advice and
10 did not)
Participants Untreated hypertensives, Italy, mean age 48 years, 42% male, ?% white, BMI<30.
Inclusion criteria: DBP 90-104 mmHg over 6 weeks, not on AHTM
Interventions LS: received low sodium dietary advice (individual counselling by GP, reinforced at each clinic visit. Main
messages (leaflet) don’t add salt at table or in cooking, restrict salty processed foods, eat more fresh/ frozen
foods and seasoning advice), USE Target: <=80,
C maintained usual diet
Outcomes BP & USE at 1,3,6, 9 & 12 mo
Notes PB: no.
OAB: no
AL: Losses excluded.
Assigned: LS 40, C 37
Follow up: LS 26, C 30 (12 mo)
Risk of bias
Item Authors’ judgement Description
Allocation concealment? No C - Inadequate
Arroll 1995
Methods RCT: ’factorial type RCT design’.
Participants Treated hypertensives, New Zealand, mean age 55 years, 52% male, ?% white.
Inclusion criteria: AHTM treated hypertension (DBP >70 to 105 mmHg or SBP >155 to 180 mmHg)
Interventions LS: on medication, asked to reduce use of high salt foods, salt added at table and in cooking (led by whom?
, group or individual?). Each given an article on BP and salt restriction, a leaflet and a book with the Na
content of common foods , USE Target: Not specified,
C: on medication, no intervention
Outcomes BP & AHTM levels following withdrawal of AHTM at 0 and 6 mo, USE at 6 mo
Notes PB: no
OAB: yes
AL: Losses excluded from BP measurement. No adjustment made for those who decreased or stopped
medication
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Arroll 1995 (Continued)
Assigned: LS 51, C 49
Follow up: LS 44, C 43 (6 mo)
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Costa 1981
Methods RCT: ’randomly divided into 2 groups’.
Participants Untreated hypertensives, Italy, age range 16-31 years, ?% male, ?% white.
Inclusion criteria: untreated borderline hypertension
Interventions LS: given a low salt diet (no data on who gave advice, group or individual counselling, materials used, or
main messages), Target: 3 g NaCl/day,
C: advised on diet with free salt intake
Outcomes BP & intra-lymphocytic sodium at 0 & 12 mo
Notes PB: no.
OAB: unclear.
AL: Not specified.
Assigned: LS 21, C 20
Follow up: LS 20, C 21 (sic)
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
HPT
Methods RCT: randomisation code ’centrally generated by computer’.
Participants Normotensives, USA, mean age 39 years, 62% male, 84% white.
Inclusion criteria: high normotensive, DBP 78-89, not on AHTM
Interventions LS: on dietary and behavioural change programme (led by personnel trained and experienced in effecting
behaviour change related to food, group sessions with individual counselling if sessions missed, newsletter
between sessions, self assessment, goal setting, participant manual, food counter, cookbook, food demon-
strations and tasting, team building exercises, tokens of accomplishment), USE Target: </=70,
C: no dietary counselling
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HPT (Continued)
Outcomes BP & USE at 0, 6, & 36 mo, % on anti-hypertensive medication
Notes PB: no
OAB: yes
AL: Participants with no follow-ups excluded; others given reading from last visit (or treated BP if higher)
.
Assigned: LS 196, C 196
Follow up: LS 174, C 191 (6 mo), LS 175, C 178 (36 mo)
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
Morgan 1978
Methods RCT: ’were divided randomly into 4 subgroups’.
Participants Untreated hypertensives, Australia, >50 years, 100% male, ethnicity not stated.
Inclusion criteria: borderline hypertension, no AHTM (DBP 95-109 mmHg as a mean of 2 or 4 readings)
Interventions LS: instructed to reduce their dietary sodium chloride intake, advice repeated at 3 months (no data on
who gave advice, group or individual counselling, materials used, or main messages), DSI Target: 70-100,
C: no dietary treatment, reviewed 6 monthly as LS group
Outcomes BP & USE at 0, 6, 12, 18, 24 mo
Notes PB: no.
OAB: yes
AL: Those with no follow-up excluded. Reading at last visit used for remainder.
Assigned: LS 34, C 33 for BP (LS 35, C 42 for mortality)
Follow up: LS 26, C 21 (24 mo) (all followed re mortality)
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
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Morgan 1987
Methods RCT: ’randomised in blocks of 4’
Participants Treated hypertensives, Australia, mean age 61 years, 100% male, ?% white.
Inclusion criteria: hypertension (DBP <85 mmHg) while on AHTM (DBP >100 uncontrolled)
Interventions LS: withdrawal of AHTM after 3 months on low sodium diet (led by whom?, no details of programme),
DSI Target: 50-75,
C: withdrawal of anti-hypertensives after 3 months, maintained normal diet
Outcomes Necessity to restart AHTM following withdrawal, USE at 0 & 9 mo
Notes PB: no.
OAB: yes
AL: Last BP reading before reinstatement was used; all had at least one follow-up.
Assigned: LS 10, C 10
Follow up: LS 10, C 10 (9 mo)
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Silman 1983
Methods RCT: ’randomisation after stratification by practice’.
Participants Untreated hypertensives, UK, aged 50 to 64, ?% male, ?% white.
Inclusion criteria: hypertension (DBP 95 - 104 mmHg over one year)
Interventions LS: general health education group package with spouses (eating sensibly, stopping smoking, regular
exercise, stress avoidance) plus taught diet (diet sheet given) lead by researcher, USE Target: 100,
C: general health education group package only
Outcomes BP & USE at 0, 1, 2, 3, 6 & 12 mo
Notes PB: no,
OAB: unclear.
AL: Losses excluded. Baseline readings for “excluded” compared with those for “included”.
Assigned: LS 12, C 16
Follow up: LS 10, C 15 (12 mo)
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
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Thaler men 1982
Methods RCT: index subjects were subdivided into two groups in such a way that the following factors were kept
balanced: sex, decade of age, SBP, AHTM, number of index persons per family, number of other persons
in family. The two groups were randomly assigned to control and salt restriction respectively’
Participants Untreated hypertensives, New Zealand, mean age 41 years, 48% male, ethnicity not stated.
Inclusion criteria: For index subjects, SBP 137-180 mmHg, some (21%) on AHTM. Family members
also included
Interventions LS: salt restriction programme for the whole family (led by a nutritionist, gradually introduced, individual
counselling, some at the family home, main messages to stop adding salt, cut out salt in cooking and
restrict high sodium foods, low sodium baking powder and baking soda were provided and a local baker
made low sodium bread, cookbook provided), USE Target: not stated,
C: asked to eat usual diet
Outcomes USE at 0 & 8 mo
Notes PB: no.
OAB: unclear.
AL: losses excluded.
Assigned: LS 80 (38 index + 42 family), C 84 (39 index + 45 family) .
Follow up: LS 69 (37 index, 19 men & 18 women), C 67 (35 index, 17 men & 18 women) (8 mo)
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Thaler women 1982
Methods as Thaler men
Participants as Thaler men
Interventions as Thaler men
Outcomes as Thaler men
Notes as Thaler men
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
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TOHP phase I
Methods RCT: ’randomisation assignments were obtained from the co-ordinating center by telephone... when
telephone contact not possible sealed opaque envelopes were used’
Participants Normotensives, USA, mean age 43 years, 71% male, 77% white.
Inclusion criteria: High normal (DBP 80 to 89 mmHg over 9 readings), not on AHTM
Interventions Regimen: LS group nutrition and behavioural counselling programme (led by nutritionists, including
food tasting and samples, problem solving exercises, shopping lists and guides, peer support and family
involvement, field trips to shops and restaurants, motivational activities, food diaries and self assessment
of sodium intake), USE Target: 80,
C: no intervention
Outcomes BP & USE at 0, 6, 12 & 18 mo
Notes PB: no
OAB: yes
AL: Participants with no follow-up reading taken as zero change; others given reading from last visit.
Assigned: LS 327, C 417
Follow up: LS 301, C 392 (12 mo),
LS 304, C 395 (18 mo)
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
TOHP phase II
Methods RCT: by telephone to TOHP co-ordinating center or sealed, opaque envelope
Participants Normotensives, USA, mean age 44 years, 67% male, 81% white.
Inclusion criteria: High normal (DBP 83 to 89 mmHg, SBP<=140 mmHg), not on AHTM. (People
unwilling to comply with intervention excluded.)
Interventions LS: dietary and behavioural change programme (led by dietitians, psychologists and health counselors,
programme as TOHP I with individual counselling as well as group sessions) intensive early on, contact
maintained later, USE Target: 70,
C: no active intervention
Outcomes BP & USE at 0, 6, 18 & 36 mo (42 or 48 mo sometimes)
Notes PB: no.
OAB: yes
AL: Those with no follow-up reading given random value from range of results; others given reading from
last visit.
Assigned: LS 594, C 596
Follow up: LS 529, C 538 (6 mo), LS 515, C 514 (36 mo)
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TOHP phase II (Continued)
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
TONE
Methods RCT: ’using a computer program each participants elegibility was confirmed prior to enrollment in the
trial, randomisation was stratified by clinic and weight status’
Participants Treated hypertensives, USA, mean age 67 years, 49% male, 76% white.
Inclusion criteria: AHTM-treated HT (DBP <85 mmHg, SBP <145 mmHg)
Interventions LS: attempted withdrawal of AHTM, group plus individual nutrition and behavioural counselling pro-
gramme (led by nutritionists), USE Target: <80,
C: attempted withdrawal of anti-hypertensives, no counselling but invited tomeetings on unrelated topics
Outcomes Combined BP, use of AHTM & CV events. USE at 0, 9, 18 & 30 mo
Notes PB: no.
OAB: yes
AL: Used survival analysis with censoring to project proportions free of endpoints.
Assigned: LS 340, C 341
Follow up: LS 310, C 314 (30 mo)
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
LS = low salt or intervention group, C= control group, AHTM = anti-hypertensive medication, BP = blood pressure, in mmHg,
SBP = systolic blood pressure, in mmHg, DBP = diastolic blood pressure, in mmHg, HT = hypertension, USE = urinary sodium
excretion, in mmol/ 24 hours, DSI = dietary sodium intake, in mmol/ 24 hours, Mo =months, CV = cardiovascular, AC = allocation
concealment, PB = participants blinded?, OAB = outcome assessors blinded?, AL = adjustment for losses
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Aberg 1989 Multifactorial management programme (dietary changes, stress management and increased physical activity)
Ambard 1904 Not randomised.
Ambrosioni 1982 Less than 6 months follow up from initial intervention
Anderson 1990 Less than 6 months follow up from initial intervention
Berglund 1989 Multifactorial management programme, less than 6 months follow up from initial intervention
Bompiani 1988 Less than 6 months follow up from initial intervention
Cappuccio 1997 Less than 6 months follow up from initial intervention
Carney 1975 Not randomised.
Corcoran 1951 Not randomised.
Dahl 1958 Not randomised.
DASH Less than 6 months follow up from initial intervention
DISH Multifactorial, reduces sodium intake, but also increases potassium intake
Dole 1951 Not randomised.
Dubbert 1995 Less than 6 months follow up from initial intervention
Erwteman 1984 Less than 6 months follow up from initial intervention
Evers 1987 Multifactorial management programme
Fagerberg 1984 Less than 6 months follow up from initial intervention
Geleijnse 1995 Multifactorial, reduces sodium intake, but also increases potassium intake
Gillum 1983 Less than 6 months follow up from initial intervention, no control group
Grimm 1990 All on salt restriction, no ’usual diet’ control
HCP Multifactorial management programme, reduction of sodium with weight loss and alcohol reduction
Henningsen 1980 Less than 6 months follow up from initial intervention (follow up between 4 and 8 months of intervention) -
suggests that later results will be published but none found and contact not established with the author
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(Continued)
Holly 1981 Less than 6 months follow up from initial intervention
Iwaoka 1994 Less than 6 months follow up from initial intervention
Jula 1990 Multifactorial management programme (sodium reduction with fat reduction)
Jula 1992a Multifactorial management programme (sodium reduction with weight and fat reduction)
Jula 1992b Multifactorial management programme (sodium reduction with weight and fat reduction)
Jula 1994 Multifactorial management programme (sodium reduction with weight and fat reduction)
Koopman 1990 The randomised part of the study only lasted 3 months, multifactorial intervention
Korhonen 1999 Less than 6 months follow up from initial intervention
Logan 1986 Compares an intensive intervention with a less intensive intervention to restrict sodium intake, but no ’usual
diet’ control group used. (This is a randomised clinical trial lasting 6 months)
MacGregor 1982a Not randomised.
MacGregor 1982b Less than 6 months follow up from initial intervention
MacGregor 1989 All on salt restriction, no ’usual diet’ control
Magnani 1976 No ’usual diet’ control
McDonald 1988 Multifactorial management programme (sodium reduction with weight and alcohol reduction)
Morgan 1988 Less than 6 months follow up from initial intervention
Muhlhauser 1993 Multifactorial management programme
Myers 1989 Less than 6 months follow up from initial intervention
Nestel 1993 Less than 6 months follow up from initial intervention
Neyses 1985 Children included
Nicholson 1986 Less than 6 months follow up from initial intervention
Nicholson 1987 Less than 6 months follow up from initial intervention
Nowson 1988 Less than 6 months follow up from initial intervention
Nugent 1984 Comparison of two different methods of salt restriction, no ’usual diet’ control
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(Continued)
ODES Multifactorial management programme
Omvik 1986 All on salt restriction, no ’usual diet’ control
Omvik 1995 All on salt restriction, no ’usual diet’ control
Parijs 1973 Not randomised.
Perera 1947 Not randomised.
Priddle 1962 Not randomised.
Rissanen 1985 No ’usual diet’ controls
Roca-Cusachs 1991 Multifactorial management programme, reduces sodium and also reduces weight, fat and alcohol
Sagnella 1987 Less than 6 months follow up from initial intervention
Shibata 1979 Not randomised.
Singer 1984 Less than 6 months follow up from initial intervention
Singer 1995 Less than 6 months follow up from initial intervention
Stamler 1989 Multifactorial management programme, reduces sodium as well as weight and alcohol with increased exercise
TAIM Multifactorial, reduces sodium intake, but also increases potassium intake
TOMHS All on salt restriction, no ’usual diet’ control
Velloso 1991 Less than 6 months follow up from initial intervention
Watt 1983 Less than 6 months follow up from initial intervention
Watt 1986 Less than 6 months follow up from initial intervention
Weinberger 1988 All on salt restriction, no ’usual diet’ control. Less than 6 months follow up from initial intervention
Wing 1984 Less than 6 months follow up from initial intervention
Zoccali 1993 Less than 6 months follow up from initial intervention
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D A T A A N D A N A L Y S E S
Comparison 1. Mortality and cardiovascular morbidity
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality 4 2393 Risk Ratio (M-H, Random, 95% CI) 0.90 [0.36, 2.24]
2 Cardiovascular morbidity 2 748 Risk Ratio (M-H, Random, 95% CI) 0.82 [0.56, 1.21]
Comparison 2. Systolic blood pressure
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Trials with 6 to 12 months of
follow up
7 2303 Mean Difference (IV, Random, 95% CI) -2.51 [-3.82, -1.21]
1.1 Normotensives 3 2124 Mean Difference (IV, Random, 95% CI) -2.31 [-3.06, -1.55]
1.2 Hypertensives 4 179 Mean Difference (IV, Random, 95% CI) -8.01 [-15.78, -0.24]
2 Trials with 13 to 60 months of
follow up
4 2347 Mean Difference (IV, Random, 95% CI) -1.12 [-1.83, -0.41]
2.1 Normotensives 3 2285 Mean Difference (IV, Random, 95% CI) -1.09 [-1.92, -0.26]
2.2 Hypertensives 1 62 Mean Difference (IV, Random, 95% CI) -1.50 [-12.60, 9.60]
3 Trials with more than 60 months
of follow up
1 128 Mean Difference (IV, Random, 95% CI) -3.80 [-7.91, 0.31]
3.1 Normotensives 1 128 Mean Difference (IV, Random, 95% CI) -3.80 [-7.91, 0.31]
3.2 Hypertensives 0 0 Mean Difference (IV, Random, 95% CI) Not estimable
Comparison 3. Diastolic blood pressure
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Trials with 6 to 12 months of
follow up
5 2211 Mean Difference (IV, Random, 95% CI) -1.21 [-1.84, -0.59]
1.1 Normotensives 3 2124 Mean Difference (IV, Random, 95% CI) -1.16 [-1.77, -0.56]
1.2 Hypertensives 2 87 Mean Difference (IV, Random, 95% CI) -4.65 [-9.33, 0.04]
2 Trials with 13 to 60 months of
follow up
4 2347 Mean Difference (IV, Random, 95% CI) -0.62 [-1.54, 0.31]
2.1 Normotensives 3 2285 Mean Difference (IV, Random, 95% CI) -0.52 [-1.05, 0.01]
2.2 Hypertensives 1 62 Mean Difference (IV, Random, 95% CI) -7.0 [-12.53, -1.47]
3 Trials with more than 60 months
of follow up
1 128 Mean Difference (IV, Random, 95% CI) -2.2 [-4.83, 0.43]
3.1 Normotensives 1 128 Mean Difference (IV, Random, 95% CI) -2.2 [-4.83, 0.43]
31Advice to reduce dietary salt for prevention of cardiovascular disease (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
3.2 Hypertensives 0 0 Mean Difference (IV, Random, 95% CI) Not estimable
Comparison 4. Urinary sodium excretion
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Urinary sodium excretion at
different times following
intervention
7 Mean Difference (IV, Random, 95% CI) Subtotals only
1.1 6-12 months following
initiation of intervention
7 2166 Mean Difference (IV, Random, 95% CI) -48.94 [-65.42, -32.
46]
1.2 13 to 60 months following
initiation of intervention
4 2787 Mean Difference (IV, Random, 95% CI) -35.53 [-47.22, -23.
85]
1.3 More than 60 months
following initiation of
intervention
1 120 Mean Difference (IV, Random, 95% CI) 10.5 [-13.83, 34.83]
Comparison 5. Dropouts
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Comparison of dropouts at
longest follow up
10 3463 Risk Ratio (M-H, Random, 95% CI) 1.04 [0.86, 1.25]
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Analysis 1.1. Comparison 1 Mortality and cardiovascular morbidity, Outcome 1 Mortality.
Review: Advice to reduce dietary salt for prevention of cardiovascular disease
Comparison: 1 Mortality and cardiovascular morbidity
Outcome: 1 Mortality
Study or subgroup Low salt Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
HPT 1/196 1/196 10.8 % 1.00 [ 0.06, 15.87 ]
Morgan 1978 4/34 5/33 55.2 % 0.78 [ 0.23, 2.64 ]
TOHP phase I 0/327 1/417 8.1 % 0.42 [ 0.02, 10.39 ]
TOHP phase II 3/594 2/596 25.9 % 1.51 [ 0.25, 8.97 ]
Total (95% CI) 1151 1242 100.0 % 0.90 [ 0.36, 2.24 ]
Total events: 8 (Low salt), 9 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.59, df = 3 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 0.22 (P = 0.82)
0.1 0.2 0.5 1 2 5 10
Favours reduced salt Favours control
Analysis 1.2. Comparison 1 Mortality and cardiovascular morbidity, Outcome 2 Cardiovascular morbidity.
Review: Advice to reduce dietary salt for prevention of cardiovascular disease
Comparison: 1 Mortality and cardiovascular morbidity
Outcome: 2 Cardiovascular morbidity
Study or subgroup Reduced salt Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Morgan 1978 6/34 5/33 12.4 % 1.16 [ 0.39, 3.45 ]
TONE 36/340 46/341 87.6 % 0.78 [ 0.52, 1.18 ]
Total (95% CI) 374 374 100.0 % 0.82 [ 0.56, 1.21 ]
Total events: 42 (Reduced salt), 51 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.44, df = 1 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 0.99 (P = 0.32)
0.1 0.2 0.5 1 2 5 10
Favours reduced salt Favours control
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Analysis 2.1. Comparison 2 Systolic blood pressure, Outcome 1 Trials with 6 to 12 months of follow up.
Review: Advice to reduce dietary salt for prevention of cardiovascular disease
Comparison: 2 Systolic blood pressure
Outcome: 1 Trials with 6 to 12 months of follow up
Study or subgroup Low sodium Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Normotensives
HPT 173 -3.8 (7.9) 191 -2.1 (8.3) 25.8 % -1.70 [ -3.36, -0.04 ]
TOHP phase I 301 -5.8 (7.5) 392 -3.9 (7.4) 33.6 % -1.90 [ -3.02, -0.78 ]
TOHP phase II 529 -5.1 (8.6) 538 -2.2 (8.1) 35.3 % -2.90 [ -3.90, -1.90 ]
Subtotal (95% CI) 1003 1121 94.6 % -2.31 [ -3.06, -1.55 ]
Heterogeneity: Tau2 = 0.07; Chi2 = 2.36, df = 2 (P = 0.31); I2 =15%
Test for overall effect: Z = 6.02 (P < 0.00001)
2 Hypertensives
Alli 1992 24 -6.6 (13.6) 27 -0.3 (16.4) 2.4 % -6.30 [ -14.54, 1.94 ]
Costa 1981 21 -14 (18.5) 20 4.3 (18.8) 1.3 % -18.30 [ -29.72, -6.88 ]
Morgan 1978 31 -3 (22.3) 31 -3 (22.3) 1.3 % 0.0 [ -11.10, 11.10 ]
Silman 1983 10 -28.7 (26.6) 15 -20 (24) 0.4 % -8.70 [ -29.18, 11.78 ]
Subtotal (95% CI) 86 93 5.4 % -8.01 [ -15.78, -0.24 ]
Heterogeneity: Tau2 = 26.52; Chi2 = 5.28, df = 3 (P = 0.15); I2 =43%
Test for overall effect: Z = 2.02 (P = 0.043)
Total (95% CI) 1089 1214 100.0 % -2.51 [ -3.82, -1.21 ]
Heterogeneity: Tau2 = 0.99; Chi2 = 11.25, df = 6 (P = 0.08); I2 =47%
Test for overall effect: Z = 3.79 (P = 0.00015)
-10 -5 0 5 10
Favours Na reduction Favours control
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Analysis 2.2. Comparison 2 Systolic blood pressure, Outcome 2 Trials with 13 to 60 months of follow up.
Review: Advice to reduce dietary salt for prevention of cardiovascular disease
Comparison: 2 Systolic blood pressure
Outcome: 2 Trials with 13 to 60 months of follow up
Study or subgroup Low sodium Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Normotensives
HPT 174 -2.8 (9.2) 177 -2.9 (9.3) 13.5 % 0.10 [ -1.84, 2.04 ]
TOHP phase I 327 -4.9 (7.8) 417 -3.2 (8.1) 38.3 % -1.70 [ -2.85, -0.55 ]
TOHP phase II 594 -0.7 (9.2) 596 0.3 (8.9) 47.8 % -1.00 [ -2.03, 0.03 ]
Subtotal (95% CI) 1095 1190 99.6 % -1.09 [ -1.92, -0.26 ]
Heterogeneity: Tau2 = 0.12; Chi2 = 2.56, df = 2 (P = 0.28); I2 =22%
Test for overall effect: Z = 2.57 (P = 0.010)
2 Hypertensives
Morgan 1978 31 -5.5 (22.3) 31 -4 (22.3) 0.4 % -1.50 [ -12.60, 9.60 ]
Subtotal (95% CI) 31 31 0.4 % -1.50 [ -12.60, 9.60 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.26 (P = 0.79)
Total (95% CI) 1126 1221 100.0 % -1.12 [ -1.83, -0.41 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 2.56, df = 3 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 3.09 (P = 0.0020)
-10 -5 0 5 10
Favours Na reduction Favours control
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Analysis 2.3. Comparison 2 Systolic blood pressure, Outcome 3 Trials with more than 60 months of follow
up.
Review: Advice to reduce dietary salt for prevention of cardiovascular disease
Comparison: 2 Systolic blood pressure
Outcome: 3 Trials with more than 60 months of follow up
Study or subgroup Low sodium Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Normotensives
TOHP phase I 58 -1.6 (11.3) 70 2.2 (12.4) 100.0 % -3.80 [ -7.91, 0.31 ]
Subtotal (95% CI) 58 70 100.0 % -3.80 [ -7.91, 0.31 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.81 (P = 0.070)
2 Hypertensives
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 58 70 100.0 % -3.80 [ -7.91, 0.31 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.81 (P = 0.070)
-10 -5 0 5 10
Favours Na reduction Favours control
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Analysis 3.1. Comparison 3 Diastolic blood pressure, Outcome 1 Trials with 6 to 12 months of follow up.
Review: Advice to reduce dietary salt for prevention of cardiovascular disease
Comparison: 3 Diastolic blood pressure
Outcome: 1 Trials with 6 to 12 months of follow up
Study or subgroup Low sodium Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Normotensives
HPT 173 -3.4 (6.6) 191 -3 (6.9) 17.5 % -0.40 [ -1.79, 0.99 ]
TOHP phase I 301 -4.4 (5.4) 392 -3.4 (5.7) 38.3 % -1.00 [ -1.83, -0.17 ]
TOHP phase II 529 -4.4 (6.7) 538 -2.8 (6.1) 42.4 % -1.60 [ -2.37, -0.83 ]
Subtotal (95% CI) 1003 1121 98.2 % -1.16 [ -1.77, -0.56 ]
Heterogeneity: Tau2 = 0.06; Chi2 = 2.54, df = 2 (P = 0.28); I2 =21%
Test for overall effect: Z = 3.77 (P = 0.00017)
2 Hypertensives
Morgan 1978 31 -3 (11.1) 31 1 (11.1) 1.3 % -4.00 [ -9.53, 1.53 ]
Silman 1983 10 -17.7 (11.4) 15 -11.4 (10.5) 0.5 % -6.30 [ -15.14, 2.54 ]
Subtotal (95% CI) 41 46 1.8 % -4.65 [ -9.33, 0.04 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.19, df = 1 (P = 0.67); I2 =0.0%
Test for overall effect: Z = 1.94 (P = 0.052)
Total (95% CI) 1044 1167 100.0 % -1.21 [ -1.84, -0.59 ]
Heterogeneity: Tau2 = 0.09; Chi2 = 4.79, df = 4 (P = 0.31); I2 =16%
Test for overall effect: Z = 3.78 (P = 0.00016)
-10 -5 0 5 10
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Analysis 3.2. Comparison 3 Diastolic blood pressure, Outcome 2 Trials with 13 to 60 months of follow up.
Review: Advice to reduce dietary salt for prevention of cardiovascular disease
Comparison: 3 Diastolic blood pressure
Outcome: 2 Trials with 13 to 60 months of follow up
Study or subgroup Low sodium Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Normotensives
HPT 174 -2.8 (6.6) 177 -3 (6.7) 23.7 % 0.20 [ -1.19, 1.59 ]
TOHP phase I 327 -4.1 (5.7) 417 -3.3 (5.7) 36.4 % -0.80 [ -1.63, 0.03 ]
TOHP phase II 594 -2.9 (6.8) 596 -2.4 (7.1) 37.3 % -0.50 [ -1.29, 0.29 ]
Subtotal (95% CI) 1095 1190 97.4 % -0.52 [ -1.05, 0.01 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.47, df = 2 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 1.94 (P = 0.053)
2 Hypertensives
Morgan 1978 31 -5 (11.1) 31 2 (11.1) 2.6 % -7.00 [ -12.53, -1.47 ]
Subtotal (95% CI) 31 31 2.6 % -7.00 [ -12.53, -1.47 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.48 (P = 0.013)
Total (95% CI) 1126 1221 100.0 % -0.62 [ -1.54, 0.31 ]
Heterogeneity: Tau2 = 0.43; Chi2 = 6.70, df = 3 (P = 0.08); I2 =55%
Test for overall effect: Z = 1.31 (P = 0.19)
-10 -5 0 5 10
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Analysis 3.3. Comparison 3 Diastolic blood pressure, Outcome 3 Trials with more than 60 months of follow
up.
Review: Advice to reduce dietary salt for prevention of cardiovascular disease
Comparison: 3 Diastolic blood pressure
Outcome: 3 Trials with more than 60 months of follow up
Study or subgroup Low sodium Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Normotensives
TOHP phase I 58 -7.5 (7.5) 70 -5.3 (7.6) 100.0 % -2.20 [ -4.83, 0.43 ]
Subtotal (95% CI) 58 70 100.0 % -2.20 [ -4.83, 0.43 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.64 (P = 0.10)
2 Hypertensives
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 58 70 100.0 % -2.20 [ -4.83, 0.43 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.64 (P = 0.10)
-10 -5 0 5 10
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Analysis 4.1. Comparison 4 Urinary sodium excretion, Outcome 1 Urinary sodium excretion at different
times following intervention.
Review: Advice to reduce dietary salt for prevention of cardiovascular disease
Comparison: 4 Urinary sodium excretion
Outcome: 1 Urinary sodium excretion at different times following intervention
Study or subgroup Low sodium Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 6-12 months following initiation of intervention
HPT 165 -35.7 (63.5) 185 -14.8 (67.2) 19.9 % -20.90 [ -34.60, -7.20 ]
Silman 1983 7 -26.4 (30.2) 11 26.4 (39.8) 11.7 % -52.80 [ -85.26, -20.34 ]
Thaler men 1982 19 -64.9 (97.9) 17 49.3 (67.7) 6.1 % -114.20 [ -168.73, -59.67 ]
Thaler women 1982 18 -31.6 (55.1) 18 8.4 (63) 9.7 % -40.00 [ -78.66, -1.34 ]
TOHP phase I 228 -55.7 (76.1) 323 2.8 (80.3) 20.1 % -58.50 [ -71.70, -45.30 ]
TOHP phase II 99 -78 (86.2) 101 -27.6 (108) 13.8 % -50.40 [ -77.45, -23.35 ]
TONE 487 -45.2 (132) 488 1.4 (132) 18.6 % -46.60 [ -63.17, -30.03 ]
Subtotal (95% CI) 1023 1143 100.0 % -48.94 [ -65.42, -32.46 ]
Heterogeneity: Tau2 = 314.21; Chi2 = 22.55, df = 6 (P = 0.00096); I2 =73%
Test for overall effect: Z = 5.82 (P < 0.00001)
2 13 to 60 months following initiation of intervention
HPT 143 -16 (68) 155 0 (71.1) 24.2 % -16.00 [ -31.80, -0.20 ]
TOHP phase I 232 -55.2 (76.9) 330 -11.3 (77.7) 25.8 % -43.90 [ -56.87, -30.93 ]
TOHP phase II 470 -50.9 (86.3) 482 -10.5 (88.5) 26.8 % -40.40 [ -51.50, -29.30 ]
TONE 487 -39.8 (143) 488 -0.3 (132) 23.3 % -39.50 [ -56.78, -22.22 ]
Subtotal (95% CI) 1332 1455 100.0 % -35.53 [ -47.22, -23.85 ]
Heterogeneity: Tau2 = 89.63; Chi2 = 8.31, df = 3 (P = 0.04); I2 =64%
Test for overall effect: Z = 5.96 (P < 0.00001)
3 More than 60 months following initiation of intervention
TOHP phase I 54 10.8 (61) 66 0.3 (75) 100.0 % 10.50 [ -13.83, 34.83 ]
Subtotal (95% CI) 54 66 100.0 % 10.50 [ -13.83, 34.83 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.85 (P = 0.40)
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Analysis 5.1. Comparison 5 Dropouts, Outcome 1 Comparison of dropouts at longest follow up.
Review: Advice to reduce dietary salt for prevention of cardiovascular disease
Comparison: 5 Dropouts
Outcome: 1 Comparison of dropouts at longest follow up
Study or subgroup Low sodium Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Alli 1992 14/40 7/37 5.6 % 1.85 [ 0.84, 4.07 ]
Arroll 1995 7/51 6/49 3.4 % 1.12 [ 0.41, 3.10 ]
HPT 21/196 18/196 9.8 % 1.17 [ 0.64, 2.12 ]
Morgan 1978 8/34 12/33 6.1 % 0.65 [ 0.30, 1.38 ]
Morgan 1987 0/10 0/10 Not estimable
Silman 1983 2/12 1/16 0.7 % 2.67 [ 0.27, 26.09 ]
Thaler men 1982 11/80 17/84 7.2 % 0.68 [ 0.34, 1.36 ]
TOHP phase I 23/327 22/417 10.9 % 1.33 [ 0.76, 2.35 ]
TOHP phase II 79/594 82/596 42.3 % 0.97 [ 0.73, 1.29 ]
TONE 30/340 27/341 14.1 % 1.11 [ 0.68, 1.83 ]
Total (95% CI) 1684 1779 100.0 % 1.04 [ 0.86, 1.25 ]
Total events: 195 (Low sodium), 192 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 6.89, df = 8 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 0.39 (P = 0.69)
0.1 0.2 0.5 1 2 5 10
Favours low sodium Favours control
A D D I T I O N A L T A B L E S
Table 1. Data - total deaths and cardiovascular events (including cardiovascular deaths)
Trial Deaths, C Deaths, LS CV events, C CV events, LS
TOHP phase I 1 (pancreatic cancer) 0
TOHP phase II 2 (causes not specified) 3 (causes not specified)
HPT 1 (no cause specified) 1 (no cause specified) ’no differences among the
treatment groups in gross
morbidity, as indicated by
periods of hospitalization,
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Table 1. Data - total deaths and cardiovascular events (including cardiovascular deaths) (Continued)
or in deaths’
Morgan 1978 5 (causes of death: 1 arthri-
tis, 1 congestive cardiac
failure, 1 cerebrovascu-
lar accident, 1 pulmonary
oedema and 1 unknown)
4 (causes of death: 1 cere-
brovascular accident bron-
chospasm, 1 myocardial
infarction, 1 congestive
cardiac failure, 1 cardiores-
piratory failure)
During first 2 years of
study 3 were treated for
congestive cardiac failure
and 0 died of CV causes, 2
died from CV causes dur-
ing the next 3 years
During the first 2 years
of study 2 were treated
for congestive cardiac fail-
ure and 1 person died (of
CVA bronchiospasm), 3
died from CV causes dur-
ing the next 3 years
TONE 46 people (2 stroke, 7 TIA,
4 MI, 17 angina, 1 con-
gestive heart failure, 3 ar-
rhythmia and 19 other car-
diovascular (further 21 CV
events (no. of people un-
clear) in the weight loss
only group))
36 people (1 stroke, 7 TIA,
2 MI, 9 angina, 2 con-
gestive heart failure, 6 ar-
rhythmia and 12 other car-
diovascular (further 23 CV
events (no. of people un-
clear) in the combined low
sodium and weight loss
group))
Alli 1992 (1 case of ischaemic heart
disease in the dropouts, but
not clear from controls or
low salt, or whether fatal)
Total 9 8 62 50
Table 2. Data - BP & urinary sodium (’mean (sd)’ for control / ’mean (sd)’ for low salt)
Trial
name
initial
SBP,
mmHg
SBP ch, 6-
12 mo
SBP ch,
13-60 mo
ini-
tial DBP,
mmHg
DBP ch,
6-12mo
DBP ch,
13-60mo
initial uri-
nary Na
Na ch, 6-
12mo
Na ch, 13-
60mo
HPT 123.9 /
124.0
6 months:-
2.1 (8.3) /
-3.8 (7.9)
(adjusted)
36
months: -
2.9 (9.3) /
-2.8 (9.2)
(adjusted)
83.0 /82.6 6 months:
-3.0 (6.9) /
-3.4 (6.6)
(adjusted)
36
months: -
3.0 (6.7) /
-2.8 (6.6)
(adjusted)
164.9 /
162.6 (cor-
rected
from 8
hour
overnight
urine sam-
ples)
6 months:
-14.8 (67.
2) / -35.7
(63.5)
(corrected
from 8
hour
overnight
urine sam-
ples)
36
months: 0.
0 (71.1) /
-16.0 (68.
0)
(corrected
from 8
hour
overnight
urine sam-
ples)
TOHP
phase I
125.1
(8.1) / 124.
8 (8.5)
12
months:
-3.9 (7.4) /
18
months: -
3.16 (8.1) /
83.9 (2.8) /
83.7 (2.7)
12
months:
-3.4 (5.7) /
18
months: -
3.3 (5.7) / -
156.4 (60.
5)/ 154.6
(59.9)
6 months:
+2.8 (80.
18
months:
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Table 2. Data - BP & urinary sodium (’mean (sd)’ for control / ’mean (sd)’ for low salt) (Continued)
-5.8 (7.5) -4.9 (7.8) -4.4 (5.4) 4.1 (5.7) 3) / -55.7
(76.1)
-11.3 (77.
7) / -55.2
(76.9)
TOHP
phase II
127.3
(6.4) /127.
7 (6.6)
6 months:-
2.2 (8.1) /-
5.1 (8.6)
36
months:
+0.3 (8.9) /
-0.7 (9.2)
85.8 (1.9) /
86.1 (1.9)
6 months:-
2.8 (6.1) /-
4.4 (6.7)
36
months: -
2.4 (7.1) / -
2.9 (6.8)
188.0 (80.
9) /186.1
(80.7)
6 months:
-
27.6 (108.
0) / -78.0
(86.2)
36
months:
-10.5 (88.
5) / -50.9
(86.3)
Morgan
1978
165 (16.7)
/160 (22.
3)
12
months:
-3 (22.3) /-
3(22.3)
24
months:
-4 (22.3) /-
5.5 (22.3)
97 (8.6) /
97 (8.7)
12
months:
+1 (11.1) /
-3 (11.1)
24
months:
+2 (11.1) /
-5 (11.1)
191 (35) /
195 (55.0)
Not given 24
months: -
11 / -38
Costa
1981
143.4 (13)
/143.3
(15)
12
months:
4.3 (18.8)
/-14.0 (18.
5) (sd im-
puted)
84.1 (7) /
84.2 (9)
12
months: -
0.2 (32.6)
/-6.1 (31.
7) (calcu-
lated sd)
Not given Not given
Thaler
1982, in-
dex men
139 (12) /
137 (14)
12
months:
+3.4 (17.
4) / -5.0
(8.3) (lev-
els of med-
ication al-
tered in
some par-
ticipants
through
trial)
90 (12) /86
(9)
12
months:
+0.8 (9.2)
/+0.6 (9.2)
(lev-
els of med-
ication al-
tered in
some par-
ticipants
through
trial)
159.5 (72.
5) / 178.1
(76.5)
12
months:
+49.3 (67.
7) / -64.9
(97.9)
Thaler
1982, in-
dex
women
148 (25) /
145 (18)
12
months:
+1.1 (14.
4) /-11.1
(24.2) (lev-
els of med-
ication al-
tered in
some par-
ticipants
through
trial)
83 (12) /86
(11)
12
months:
+2.8 (8.5) /
-6.8 (11.9)
(lev-
els of med-
ication al-
tered in
some par-
ticipants
through
trial)
120.1 (41.
5) /118.0
(39.9)
12
months:
+8.4 (63.
0) / -31.6
(55.1)
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Table 2. Data - BP & urinary sodium (’mean (sd)’ for control / ’mean (sd)’ for low salt) (Continued)
Silman
1983
160.5 /
165.3
12
months:
-20.0 (24.
0) /-28.7
(26.6)
98.3 /98.8 12
months: -
11.
4 (10.5) /
-17.7 (11.
4)
146.5 /
150.8
12
months:
26.4 (39.
8) / -26.4
(30.2)
Alli 1992 148.3 (10.
6) / 150.8
(8.7)
12
months:
-0.3 (16.4)
/-6.6 (13.
6) (sd im-
puted)
97.2 (3.8) /
97.0 (3.1)
12
months: -
2.7 (16.6)
/ -6.4 (18.
5) (sd cal-
culated)
177.3 (61.
7) /177.3
(61.0)
12
months:
-4.2 /+8.6
(data mea-
sured off
graph)
Morgan
1987
143 (15.8)
/143 (15.
8)
9 months:
+35 (25.7)
/+12 (21.
5) (sd im-
puted, lev-
els of med-
ication al-
tered in
some par-
ticipants
through
trial)
81 (6.3) /
83 (6.3)
9 months:
+17 (28.7)
/+7 (22.2)
(sd calcu-
lated, lev-
els of med-
ication al-
tered in
some par-
ticipants
through
trial)
163 (50.6)
/168 (37.
9)
-8 / -93
Arroll
1995
145.3 (15.
7) /145.4
(15.9)
6 months:
-6.2 (21.0)
/-9.1 (21.
7) (sd im-
puted, lev-
els of med-
ication al-
tered in
some par-
ticipants
through
trial)
94.0 (9.8) /
86.4 (9.9)
6 months:
-4.8 (36.1)
/ -1.7 (34.
9) (sd cal-
cu-
lated, lev-
els of med-
ication al-
tered in
some par-
ticipants
through
trial)
Not given Not given
TONE 128 (9) /
129 (9)
Not given 71 (7) /72
(7)
Not given 146.2 /
145.3
9 months:
+1.
4 (132) / -
45.2 (132)
(data in-
clude those
in weight
30
months:-0.
3 (132) /-
39.8 (143)
(data in-
clude those
in weight
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Table 2. Data - BP & urinary sodium (’mean (sd)’ for control / ’mean (sd)’ for low salt) (Continued)
loss group
with con-
trol,
and weight
loss plus
sodium re-
duction
with inter-
vention)
loss group
with con-
trol,
and weight
loss plus
sodium re-
duction
with inter-
vention)
Table 3. Meta-analysis, sugrouping and sensitivity analysis results
Outcome Time Type of anal-
ysis
Description Number of
studies
WMD 95% CI p for hetero-
geneity
Systolic
blood pressure
(mmHg)
6 to 12
months
Overall meta-
analysis
7 -2.5 -3.8 to -1.2 0.08
Systolic
blood pressure
(mmHg)
6 to 12
months
Sensitivity
analysis
Drop imputed
standard devi-
ations
5 -2.3 -3.0 to -1.7 0.57
Systolic
blood pressure
(mmHg)
6 to 12
months
Sensitivity
analysis
Small-
est calculated
standard devi-
ations
7 -3.1 -4.8 to -1.3 <0.01
Systolic
blood pressure
(mmHg)
6 to 12
months
Sensitivity
analysis
Allocation
concealment
3 -2.3 -3.1 to -1.6 0.31
Systolic
blood pressure
(mmHg)
6 to 12
months
Sensitivity
analysis
Including
weight arms
7 -1.6 -3.0 to -0.2 <0.01
Systolic
blood pressure
(mmHg)
6 to 12
months
Subgrouping Normoten-
sives
3 -2.3 -3.1 to -1.6 0.31
Systolic
blood pressure
(mmHg)
6 to 12
months
Subgrouping Untreated hy-
pertensives
4 -8.0 -15.8 to -0.2 0.15
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Table 3. Meta-analysis, sugrouping and sensitivity analysis results (Continued)
Systolic
blood pressure
(mmHg)
13 to 60
months
Overall meta-
analysis
4 -1.1 -1.8 to -0.4 0.46
Systolic
blood pressure
(mmHg)
13 to 60
months
Sensitivity
analysis
Allocation
concealment
3 -1.1 -1.9 to -0.3 0.28
Systolic
blood pressure
(mmHg)
13 to 60
months
Sensitivity
analysis
Including
weight arms
4 -0.5 -1.4 to 0.4 0.10
Systolic
blood pressure
(mmHg)
13 to 60
months
Subgrouping Normoten-
sives
3 -1.1 -1.9 to -0.3 0.28
Systolic
blood pressure
(mmHg)
13 to 60
months
Subgrouping Untreated hy-
pertensives
1 -1.5 -12.6 to 9.6 -
Systolic
blood pressure
(mmHg)
> 60 months Overall meta-
analysis
1 -3.8 -7.9 to 0.3 -
Diastolic
blood pressure
(mmHg)
6 to 12
months
Overall meta-
analysis
5 -1.2 -1.8 to -0.6 0.31
Diastolic
blood pressure
(mmHg)
6 to 12
months
Sensitivity
analysis
Drop imputed
standard devi-
ations
imputed stan-
dar deviations
no longer used
for diastolic
blood pressure
Diastolic
blood pressure
(mmHg)
6 to 12
months
Sensitivity
analysis
Small-
est calculated
standard devi-
ations
imputed stan-
dar deviations
no longer used
for diastolic
blood pressure
Diastolic
blood pressure
(mmHg)
6 to 12
months
Sensitivity
analysis
Allocation
concealment
3 -1.2 -1.8 to -0.6 0.28
Diastolic
blood pressure
(mmHg)
6 to 12
months
Sensitivity
analysis
Including
weight arms
7 -0.7 -1.5 to 0.1 0.05
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Table 3. Meta-analysis, sugrouping and sensitivity analysis results (Continued)
Diastolic
blood pressure
(mmHg)
6 to 12
months
Subgrouping Normoten-
sives
3 -1.2 -1.8 to -0.6 0.28
Diastolic
blood pressure
(mmHg)
6 to 12
months
Subgrouping Untreated hy-
pertensives
2 -4.7 -9.3 to 0.0 0.67
Diastolic
blood pressure
(mmHg)
13 to 60
months
Overall meta-
analysis
4 -0.6 -1.5 to 0.3 0.08
Diastolic
blood pressure
(mmHg)
13 to 60
months
Sensitivity
analysis
Allocation
concealment
3 -0.5 -1.1 to 0.0 0.48
Diastolic
blood pressure
(mmHg)
13 to 60
months
Sensitivity
analysis
Including
weight arms
4 -0.3 -1.0 to 0.4 0.06
Diastolic
blood pressure
(mmHg)
13 to 60
months
Subgrouping Normoten-
sives
3 -0.5 -1.1 to 0.0 0.48
Diastolic
blood pressure
(mmHg)
13 to 60
months
Subgrouping Untreated hy-
pertensives
1 -7.0 -12.5 to -1.5 -
Diastolic
blood pressure
(mmHg)
> 60 months Overall meta-
analysis
1 -2.2 -4.8 to 0.4 -
Sodium ex-
cretion (mmol
Na/ 24 hours)
6 to 12
months
Overall meta-
analysis
6 -48.9 -65.4 to -32.5 <0.01
Sodium ex-
cretion (mmol
Na/ 24 hours)
6 to 12
months
Sensitivity
analysis
Allocation
concealment
4 -43.6 -62.6 to -24.6 <0.01
Sodium ex-
cretion (mmol
Na/ 24 hours)
6 to 12
months
Sensitivity
analysis
Including
weight arms
6 -44.3 -58.4 to -30.2 <0.01
Sodium ex-
cretion (mmol
Na/ 24 hours)
13 to 60
months
Overall meta-
analysis
4 -35.5 -47.2 to -23.9 0.04
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Table 3. Meta-analysis, sugrouping and sensitivity analysis results (Continued)
Sodium ex-
cretion (mmol
Na/ 24 hours)
13 to 60
months
Sensitivity
analysis
Allocation
concealment
4 -35.5 -47.2 to -23.9 0.04
Sodium ex-
cretion (mmol
Na/ 24 hours)
13 to 60
months
Sensitivity
analysis
Including
weight arms
4 -33.3 -42.0 to -24.6 0.05
Sodium ex-
cretion (mmol
Na/ 24 hours)
> 60 months Overall meta-
analysis
1 10.5 -13.8 to 34.8 -
Dropouts Latest follow
up
Overall meta-
analysis
Dropouts in
low sodium vs
control groups
10 Relative risk =
1.04
0.86 to 1.25 0.55
Table 4. Meta-regression results, effects on SBP at 6 to 12 months
Explanatory variable Slope coef (95% CI) Constant No. of RCTs
Trials on normotensives and hy-
pertensives
Mean baseline SBP -0.173 (-0.356 to 0.010) 19.5 7
Mean change in urinary sodium
excretion (6 to 12 months)
0.013 (-0.049 to 0.075) -1.68 4
Mean age of participants at
baseline
0.118 (-0.188 to 0.424) -7.46 7
Trials of normotensives only
Mean baseline SBP -0.362 (-0.826 to 0.102) 43.3 3
Mean change in urinary sodium
excretion (6 to 12 months)
0.013 (-0.057 to 0.084) -1.63 3
Mean age of participants at
baseline
-0.213 (-0.630 to 0.203) 6.81 3
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Table 5. Characteristics of systematic reviews on salt and blood pressure
Review Inclusion
criteria
RCTs
only?
Normo/
hyper ten-
sive
Median
duration
No. trials
(n)
Fall in Na
excretion
WMD
SBP
(95%CI)
WMD
DBP
(95%CI)
Qual-
ity assess-
ment
Graudal
1998
Popu-
lation:
mean age
>15 years,
Interven-
tion: low
sodium
or high
sodium
diet,
no con-
founding,
Outcome:
urinary
sodium
excretion
measured,
systolic,
diastolic or
mean BP
reported
Yes,
random al-
location,
parallel or
crossover
Nor-
motensive
8 (4-1100)
days
56 (2581) weighted
mean 160
-1.2 (-0.6
to -1.8)
-0.26 (+0.
3 to -0.9)
QA: sub-
grouping
by
open/ sin-
gle blind or
double
blind
method
did not af-
fect results.
Notes: Sta-
tistical het-
erogeneity
noted
Graudal
1998
Hyperten-
sive
28 (4-365)
days
58 (2161) weighted
mean 118
-3.9 (-3.0
to -4.8)
-1.9 (-1.3
to -2.5)
Midgley
1996
Popu-
lation:
human,
not on
antihy-
pertensive
drugs, In-
tervention:
dietary
sodium in-
tervention,
Outcome:
diastolic
and sys-
tolic BP
measure-
ment,
urinary
sodium
Yes, ran-
domised
controlled
trials
(crossover
or parallel
design)
Nor-
motensive
14 (4-
1095) days
28 (2374) weighted
mean 125
(95% CI
95-156)
-1.6 (-2.41
to -0.89)
-0.5 (-1.18
to 0.11)
QA: Sig-
nificant
hetero-
geneity
seen,
reduced
but not
eliminated
when stud-
ies sub-
grouped
according
to quality
charac-
teristics.
Notes:
Evidence
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Table 5. Characteristics of systematic reviews on salt and blood pressure (Continued)
excretion-
Design:
English
language,
full-length
journal
articles
of publica-
tion bias
provided
Midgley
1996
Hyperten-
sive
29 (4 -
730) days
28 (1131) Weighted
mean 95
(95% CI
71-119)
-5.9(-7.77
to -4.12)
-3.8 (-4.78
to -2.9)
Law 1991 Popula-
tion: not
on antihy-
pertensive
drugs, In-
tervention:
dietary
sodium
restriction,
not con-
founded,
Outcome:
24 hour
urine
collection,
systolic
and/or
diastolic
BP
No. Nor-
motensive
1.5 (0.7 to
16) weeks
15 (?) Not stated Not stated Not stated QA: Qual-
ity not as-
sessed.
Notes: In-
di-
vidual trial
data com-
pared with
pooled ob-
serva-
tional data,
rather than
pooled to-
gether
Law 1991 Hyperten-
sive
5 (0.7 to
104) weeks
63 (?) Not stated Not stated Not stated
Law 1991 The review
estimates
that in
people
aged 50-
59 a re-
duction in
50mmol
Na /24
hours
would lead
to a fall of
5mmHg
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Table 5. Characteristics of systematic reviews on salt and blood pressure (Continued)
in systolic
and 2.
5mmHg
in diastolic
BP in
normoten-
sives, and
a fall of
7 and 3.
5mmHg
respec-
tively in
hyperten-
sives
Cutler
1997
Popula-
tion: adult
human,
Inter-
vention:
sodium
goals
28-273
mmol/
24 hours,
no con-
founding
allowed,
Outcome:
lab-based
measure
of sodium
intake,
systolic
and/or di-
astolic BP
measured
Yes, ran-
domised
controlled
trials
(crossover
or
parallel de-
sign), pub-
lished only
Nor-
motensive
1
(0.5 to 36)
months
12 (1689) Median
~90 (range
16 to 210)
-1.5 (-2.1
to -1.0)
-0.8 (-1.3
to -0.3)
QA:
subgroup-
ing by dou-
ble blind
or not had
no signifi-
cant effect
on overall
outcome.
Notes: re-
gres-
sion analy-
ses used for
publi-
cation bias
failed to re-
ject the
null
hypothesis
Cutler
1997
Hyperten-
sive
2 (1-24)
months
22 (1043) Median
~71 (range
27 to 171)
-3.8 (-4.9
to -2.8)
-2.1 (-2.8
to -1.5)
Alam 1999 Popu-
lation: hu-
man el-
derly (>50
years), In-
tervention:
changes in
dietary
Yes, pub-
lished En-
glish-lan-
guage ran-
domised
controlled
trials,
crossover
Nor-
motensive
(2 trials) or
with essen-
tial hyper-
tension (9
trials)
14 (9-104)
weeks
11 (485) Median 80
(range 23
to 260)
-5.6(-6.9
to -4.3)
-3.5 (-4.4
to -2.6)
QA: qual-
ity assess-
ment score
tended
to be high
(av-
erage score
51Advice to reduce dietary salt for prevention of cardiovascular disease (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 5. Characteristics of systematic reviews on salt and blood pressure (Continued)
NaCl,
Outcome:
blood pres-
sure
or parallel >70%)
Ebrahim
and Davey
Smith
1998Ebrahim
and Davey
Smith
1998
Popula-
tion: adult
hu-
mans, In-
tervention:
dietary
sodium re-
duction vs.
con-
trol, Out-
come: di-
astolic and
systolic BP
measure-
ment, uri-
nary
sodium ex-
cretion
Yes, ran-
domised
controlled
trials of at
least
6 months
duration
Nor-
motensive
Not stated 2 (1095) Not stated -1.3 (-2.7
to +0.1)
-0.8 (-1.8
to +0.2)
QA: Qual-
ity not as-
sessed.
Ebrahim
and Davey
Smith
1998
Hyperten-
sive
Not stated 6 (466) Not stated -2.9(-5.8
to 0.0)
-2.1 (-4.0
to -0.1)
This
review, 6 to
12 months
Popula-
tion: adult
human,
Inter-
vention:
sodium
reduced
diet vs.
usual diet,
Outcome:
urinary
sodium
excretion,
systolic
and/or
diastolic
BP mea-
surements
taken 6 to
12 months
Yes, paral-
lel ran-
domised
controlled
trials
Nor-
motensive
6 (6 to 12)
months
3 (2124) Weighted
mean 43
(95% CI
16 to 70)
-2.3 (-3.1
to -1.6)
-1.2 (-1.8
to -0.6)
QA: Sensi-
tivity anal-
y-
sis (remov-
ing trials
where allo-
cation con-
cealment is
poor
or unclear)
had no ef-
fect on di-
rection or
signifi-
cance of re-
sults
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Table 5. Characteristics of systematic reviews on salt and blood pressure (Continued)
or more
than 12
months
after inter-
vention
This
review, 6 to
12 months
Hyperten-
sive
12
(12 to 12)
months
4(179) weighted
mean 48
(95% CI
33 to 63)
-8.0 (-15.8
to -0.2)
-4.5 (-8.7
to -0.4)
This re-
view, 13 to
60 months
Nor-
motensive
36
(18 to 36)
months
3 (2285) weighted
mean 34
(95% CI
19 to 50)
-1.1(-1.9
to -0.3)
-0.5 (-1.1
to 0.0)
This re-
view, 13 to
60 months
Hyperten-
sive
24 months 1(62) weighted
mean 40
(95% CI
22 to 57)
-1.5 (-12.6
to 9.6)
-7.0 (-12.5
to -1.5)
F E E D B A C K
Comments on the Cochrane Review by Hooper et al
Summary
Previous meta-analyses have lumped both short term and long term trials together [1,2] and therefore Hooper et al’s meta-analysis is an
important attempt to look at whether longer term salt reduction (i.e. more than 6 months) in randomised trials causes a fall in blood
pressure [3,4].
Given the inherent difficulty of reducing salt intake long term, it is not surprising that they only found a small reduction of 2 g/
day in the long-term trials from an intake of around 10 g/day. This contrasts with a recommended reduction in nearly all western
countries of at least 5 to 6 g/day from the now almost universal intake of 10 to 12 g/day. It would come, therefore, as no surprise that a
small reduction (2 g/day) in salt intake compared to the public health recommended reduction only causes a small, but in their meta-
analysis, a highly significant reduction in blood pressure. Nevertheless, this small reduction in adult population blood pressure would
be expected to have a significant effect on reducing strokes, heart attacks [5,6], and heart failure, the commonest causes of death and
disability in the western world.
There are important points, which Hooper et al fail to mention in the discussion section of their paper. For instance, other meta-
analyses have demonstrated a dose response to salt restriction [7]. Therefore, if it was possible to reduce salt intake by a larger amount
(e.g. by reducing the salt content of processed food) the fall in blood pressure and the benefits would be even larger.
There are errors and misquotation of the relevant literature in the meta-analysis. They claim that interventions used were highly
intensive, but the majority of studies gave no details as to what advice was offered. The fact that very few of these studies were successful
in reducing salt intake more than 1 or 2 g/day casts further doubt on this unwarranted assertion. Furthermore, as the majority of salt
comes from processed foods, it is absolutely vital to provide processed foods with less salt in these studies. Unfortunately, only a few of
the studies that they included provided reduced salt foods.
In the meta-analysis, the follow up study of the TOHP trial [8] was included as an over 60 months intervention trial, but salt intake
was in fact only reduced for 18 months, after which all participants returned to their normal diet. It is not, therefore, as Hooper et al
state, a 60-month trial of salt restriction.
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Alderman claimed that reducing salt intake in treated hypertensives led to myocardial infarction [9]. Detailed examination of the paper
and analysis of the urinary creatinines that were provided later clearly demonstrated that the group on the low salt intake were in fact
there because most of them had collected an inadequate 24 hour urine and therefore had less salt in the urine as it was an incomplete
urine collection. There was no evidence that they were on a lower salt intake. Furthermore, there was only one 24 hour urine at the time
of entry and no further measurements were made during the study, so the study suffered from the defect that there was no evidence
that the group who were said to have been on a lower salt intake were in fact on a lower salt intake at entry and no attempt was made to
measure salt intake during the rest of the study. In the second study [10] taken from the NHANES-1 Dietary Survey, the First National
Health and Nutrition Examination survey in the USA, no assessment of discretionary salt (salt added to the table and cooking) was
made. As the study was conducted in the 1980s, at this time approximately half of all salt intake would be in the form of discretionary
salt. Therefore the assessment of total dietary salt intake is likely inadequate. Those on a lower salt intake were on a calorie intake that
was equivalent to a starvation diet and yet were heavier than those who were said to be on a higher salt intake, in spite of the fact
that these latter people had a much higher calorie intake. These two studies [9,10] cannot be quoted as evidence about the long-term
cardiovascular effects of salt reduction. We suggest reading correspondence following these papers [11-16].
Hooper et al’s meta-analysis has been previously published in the British Medical Journal [4]. It appears that their current Cochrane
review has not been altered and, in particular, no attempt has been made to respond to criticism raised at the time [17,18]. For instance,
Hooper et al claim that an increase in cholesterol occurs with salt restriction and quoted the meta-analysis by Graudal et al [2]. The
latter meta-analysis included trials of very short term, mainly for only 5 days, and large changes in salt intake, e.g. 20 g/day. With these
acute large changes in salt intake there are large changes in blood volume and it is not surprising that in the short term there is a change
in cholesterol. However, it has been well demonstrated in longer-term trials of more modest reductions in salt intake that there is no
change in cholesterol [7].
In spite of these problems with their meta-analysis, we agree with the conclusions that if salt intake is reduced by small amounts there
are small but significant reductions in blood pressure. Indeed, these blood pressure falls fit almost exactly with the dose response that
we found in a more recent meta-analysis of salt reduction [7].
In our opinion the conclusion from their study should read: “A meta-analysis of randomised longer term salt reduction trials has shown
the difficulty of reducing salt intake in the long term without the provision of processed foods with less salt, as the mean salt reduction
in the studies was only 2 g/day. Nevertheless, this small reduction in salt intake did cause a significant fall in blood pressure, which, on
a population basis, would lead to a significant reduction in strokes, heart attacks and heart failure. Therefore, even small reductions
in salt intake would be very worthwhile and in developed countries are practical to carry out. There is no evidence that this small
reduction in salt intake would have any harmful effect. It could easily be implemented by the food industry in a very short time as it
would only mean a 15 to 20% reduction in the salt content of all processed, canteen, restaurant and fast foods. This reduction in salt
concentration of foods is not detectable and can easily be achieved, as shown by the experience of a leading supermarket in the UK
where such reductions have already been implemented. If larger reductions in salt intake could be implemented in the population the
benefits would be large”. Indeed, the authors’ own press release states that the difficulty for people to reduce their salt intake is “because
most salt comes from processed and ready made foods. Efforts by the government to reduce hidden salt in foods such as bread and
cereals may be more effective as no dietary change is necessary” [19].
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Reply
The Authors Reply:
The stated objective was to assess the long-term effects of advice to restrict dietary sodium, rather than the effect of the actual sodium
restriction (as advice is rarely followed perfectly and over a long period of time). The effect of such advice is important as it is commonly
used in primary care and is a central part of the guidelines produced by bodies such as the British Hypertension Society [1].
Despite the difficulties inherent in reducing sodium intake, individual advice does result in a significant but small reduction in blood
pressure. If this small reduction could be achieved across entire populations, it would be reasonable to expect some benefits in terms
of cardiovascular disease events avoided. But it is simply unrealistic to imagine that interventions as intensive as those used in the trials
reviewed here could be applied population wide.
Of the 2349 people involved in the studies which measured blood pressure at 13 to 60 months (see forest plot 02, 02), 2287 had been
involved in intensive and comprehensive behavioural change program to help them reduce their salt intake (for the 6 to 12 month
outcome period 2124 of 2303 had intensive interventions, forest plot 02, 01). As an example, the least intensive of these programs, the
HPT study, included group sessions (17 sessions over the first year, 28 over 3 years) with individual counselling if sessions were missed,
a newsletter between sessions, self assessment, goal setting, a participant manual, a food counter, cookbook, food demonstrations and
tastings, team building exercises and tokens of accomplishment, led by personnel trained and experienced in effecting behaviour change
related to food. This type of intervention is not realistic at a population level.
Meta-analyses have only been able to demonstrate a dose response of blood pressure to sodium reduction when they have artificially
forced the regression line through the origin. Where this has not been done no dose response has been seen.
See comments above on intensity of dietary advice. While several small trials were included with little information on how or what
advice was provided, the majority of people involved in trials (who provided the bulk of the information on blood pressure response
after 1 year) were in the larger, well documented trials with intensive interventions.
A different meta-analysis is required to assess the effect of interventions where large quantities of low sodium foods are provided to
participants - this would be an unusual addition to dietary advice in primary or secondary care, but is a valid and interesting question
in its own right.
These issues regarding the TOHP trial are already discussed within the results section of the review (paragraph 4).
The two cohort studies mentioned by He and MacGregor are not included in the review, but are mentioned very briefly in the
discussion. The section states that a weakness of our review is its lack of ability to assess the effect of advice to reduce sodium on
cardiovascular morbidity and mortality. Six cohort studies are quoted, and show a variety of conclusions about the effects of salt on
death and cardiovascular health. The point being made is that we cannot be entirely sure that a reduction in blood pressure through
advice to reduce salt intake will result in only beneficial effects on health. Ideally we would have some direct evidence that health
benefits accrue.
Clearly, also, the cohort studies have large potential flaws, which make reliance on their conclusions unhelpful. Randomised controlled
trials, and systematic reviews of randomised controlled trials are needed to understand the health effects of changes in diet.
In Graudal’s review [2] 653 participants were involved in the meta-analysis which showed a significant increase in total cholesterol
after around 7 days of a low sodium diet (and 517 participants were involved in the significant increase in LDL at 7 days). In the
quoted review by He and MacGregor [7] only three trials contribute information on total cholesterol (81 participants) and fewer on
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LDL. It would be extremely surprising if this number of participants did show a significant effect on total cholesterol or LDL. In this
circumstance lack of a significant effect does not rule out a clinically important effect of salt reduction on lipids in the longer term.
We disagree with the conclusions proposed by He and MacGregor; we did not assess palatability of processed food, or detectability of
a 20% salt reduction in such foods. We cannot be certain from our review what the health effects of a general reduction in sodium
might be. We stand by our conclusions as stated in the review.
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Comments on the Review by Hooper et al
Summary
Health care providers, researchers and policy makers need systematic reviews for rational decision making, because they are inundated
with otherwise unmanageable amounts of information [1]. It follows that the title and the Reviewers’ Conclusions on the front page
constitute critical elements of a Cochrane Review.
In the Review by Hooper et al [2] we find both the title and conclusions misleading. This is especially regrettable since both the title
and the conclusions were clear and informative in their earlier BMJ version of the same meta-analysis [3].
Their BMJ paper is entitled ’Systematic review of long-term effects of advice to reduce dietary salt in adults’ and their conclusion is
that the 11 trials ’provided only small reductions in blood pressure and sodium excretion’. Thus the BMJ paper clearly refers to a meta-
analysis of studies of effectiveness (a measure of the extent to which an intervention has its intended effect) in which the outcome was
limited by poor dietary compliance, rather than efficacy (a measure of what can be achieved when an intervention is fully implemented).
Effectiveness is measured by the outcome of offering a treatment or other intervention to people who are free to accept or reject it, as
they might ordinarily do [4], complying only as well as their personal inclination and social or economic circumstances allow. Efficacy
is measured from the outcome when a specified treatment or other intervention is fully applied [4].
The title of the Cochrane Review no longer makes this distinction clear. The title this time is ’Reduced dietary salt for prevention of
cardiovascular disease’ and the conclusion is that 11 long-term trials provided ’only minimal reductions in blood pressure’. Hence, both
the title and conclusion ignore the fact that the degree of dietary sodium reduction achieved in these trials was only modest, thereby
limiting the effectiveness of the intervention. Their Cochrane Review implies that these authors are publishing a finding about efficacy
and concludes that low salt diets are not very efficacious, which is untrue - significant reductions in blood pressure can be achieved
in both hypertensives and normotensives when the dietary intervention is more fully applied, as it was in the short DASH Sodium
study in which all of the food was supplied by the study organisers [5] and in longer studies where it was also more fully applied [6]. A
Cochrane Review that misrepresents limited effectiveness as limited efficacy is seriously misleading to policy makers expecting guidance,
and it limits the value of the Cochrane Collaboration - the very institution that commemorates the late Archie Cochrane, who made
effectiveness a standard term in epidemiology [7,8]. The correspondence after their BMJ paper drew attention to good evidence of
the efficacy of a lower salt intake, and the important implication for policy makers that a better supply of suitable foods will improve
dietary compliance and effectiveness [9].
We discuss the fallacy of confusing effectiveness with efficacy at greater length in our comments on the Cochrane Review by Jürgens
and Graudal [10].
Call for long-term randomised controlled trials
The authors conclude that we need long-term randomised controlled trials (RCTs) of a lower salt intake of a size and duration that will
enable us to measure mortality and morbidity outcomes. It is unrealistic to call for such trials without suggesting ways of removing the
fatal obstacles. Some of these have already been published [11], but the recommendations of JNC 7 have raised new obstacles that we
consider insurmountable.
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After reviewing no less than 11 inconclusive long-term effectiveness trials, Hooper et al have given no reasons for believing that the
proposed long-term RCTwould provide anything but yet another inconclusive effectiveness trial. The alternative of a long-term efficacy
trial would explode the budget with the astronomical cost of catering for all the meals eaten throughout the day by thousands of people
for one to three decades.
Moreover JNC 7 has added a new obstacle. It gave high-normal blood pressure a new name - prehypertension - for which JNC 7 has
advocated nonpharmacological treatment, including the low salt diet of the intervention group [12]. This means the trial could recruit
only subjects with blood pressure (BP) below 120/80, because it would be unethical to randomise subjects with prehypertension to the
control group, postponing the expected late endpoints for perhaps another decade or more.
Secondly for ethical reasons it would be mandatory to give all members of the control group treatment for prehypertension as soon as
their BP rose above 120/80, which would mean their having to adopt the low salt diet of the intervention group. This would result in
the gradual (and probably near-complete) erosion of the control group as members leave on account of the rise of BP with age that
would have provided the difference in long-term endpoints.
In our view the long-term RCT was never feasible because the ethical requirement to keep the BP of all members of the control group
permanently <140/90 as soon as they became hypertensive would have greatly postponed the expected late endpoints. The new ethical
requirement to treat prehypertension by allowing the control group member to share the diet of the diet group is in our view an
insurmountable obstacle.
What would Cochrane’s advice be today? It is easy to predict from his writings what he might have said and done. Cochrane knew that
RCTs are unable to answer a large number of very important questions in public health, on account of practical, ethical, economic or
other obstacles [8]. Cochrane would obtain other evidence. Some of that evidence might be observation and inference and as much as
possible would be experimental. Our belief is that the existing evidence would allow Cochrane to approve of government initiatives to
achieve the 50% reduction in the sodium content of processed foods that the American Public Health Association has called for (with
explicit support from JNC 7).
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Reply
The Authors Reply:
“Reduced dietary salt for prevention of cardiovascular disease” is an appropriate title for aCochrane review as it follows the recommended
format of “intervention for disease”. The title is not declarative and it is necessary for the reader to examine the abstract for the objectives,
which make it totally clear that we are assessing the effect of dietary advice. However, after consultation with the Co-ordinating Editor
of the Cochrane Hypertension Group, we have altered the title to ’Advice to reduce dietary salt for prevention of cardiovascular disease’.
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The data cited which ’offers good evidence of the efficacy of a lower salt intake’ is the following:
Reducing the current average salt consumption in Britain by 3 g/day (about one third) would reduce average blood pressure by about 5
mm Hg systolic in people over 50 and thereby reduce the incidence of heart attack and strokes by about 15% and 22% respectively.[1]
A reduction of 6 g/day would reduce blood pressure by about twice as much with a corresponding additional reduction in the incidence
of heart attacks and stroke. Reducing salt intake generally would thus have a major impact in the prevention of cardiovascular disease.
Law’s study from which this information is derived used a very unique methodology. Instead of pooling randomised controlled trials
(and there are many reviews that do, see additional table 05), observational studies were pooled and were then compared with the
results of the controlled trials (most of which were not randomised) and determines that they are not significantly dissimilar. In doing
this he comes up with an effect size of a very different order than all other published systematic reviews. This is not a credible way to
pool trial evidence. We drew attention to this in our response to the criticisms of our BMJ review.[2]
The estimate of the effect that this would have on mortality and morbidity was taken from evidence from a prospective study, but
different prospective studies come up with very different relationships to mortality and morbidity (see discussion section of this review).
It is not reasonable to pick only the evidence that supports the most optimistic view.
To assess the effect of dietary advice to reduce salt intake on cardiovascular morbidity is not necessarily difficult. Of the four large trials
included in this review (those including at least 250 participants) information on cardiovascular morbidity that could be used in meta-
analysis was provided by only one (TONE [3]). If details were published of the ’in study’ cardiovascular morbidity for the other three
(a further 2326 participants) this would be likely to provide a reasonable amount of extra information (and if the protective trend of
low salt advice seen in the TONE trial was followed we may even see statistically significant protection from cardiovascular events in
the low salt advice group). We did try to contact the trialists for this data but received no replies.
Although it might be argued that these trials have now been completed, long-term follow up of trial participants who received intensive
dietary advice, the effects of which might reasonably be expected to induce life-long behaviour change, may be informative. However,
to check the validity of such long-term evaluations, both the extent of dietary salt reduction advice provided to the control groups at
the close of the studies, or since, and the maintenance of lower salt intake among the intervention groups does need to be assessed.
These are the logical first inexpensive steps to take. If these are not enough, then, a new (and large) trial of dietary advice should
be contemplated. Investigators of cholesterol-lowering by either diet or drugs were not thwarted by the scale of trials necessary to
demonstrate convincing effects.
The most important point is that trialists of dietary advice have failed to contribute relevant data to the public domain, and, as we
found were unwilling to enter into data sharing with systematic reviewers. Perhaps the challenge is for trialists in this area to form
collaboration with the aim of conducting an individual patient data meta-analysis. It should be noted we have never advocated a long-
term efficacy trial.
The ethical issues inherent in any trial depend on the degree of clinical equipoise and as the salt debate illustrates, extreme views are
held which makes it likely that sufficient clinicians in equipoise would be found. With ever-lower levels of “normal” blood pressure
being defined it will be necessary to advance the knowledge base by conducting further trials.
What Archie Cochrane would have decided to do in these circumstances is a matter of speculation and of little relevance to the current
issues. The importance of government initiatives to reduce sodium in processed foods depends on the efficacy, rather than effectiveness,
of salt reduction and the DASH [4] salt study has leant serious weight to the importance of salt reduction to reduce blood pressure,
but also of diets with increased fruit and vegetable intake, reduction in saturated fats, adequate whole grains, calcium, protein etc. This
probably cannot all be achieved from processed foods, however low in salt they may be.
We stand by the conclusions as stated in the review.
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